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Summary 
Posttranslational modifications are involved in basically all cellular processes. Some of them have 
been studied quite extensively, such as phosphorylation and ubiquitination. Others, mono-ADP-
ribosylation for example, have currently barely been investigated. Mono-ADP-ribosylating enzymes 
transfer an ADP-ribose moiety from the cofactor NAD
+
 onto a target substrate. ARTD10 has been 
demonstrated to be an enzyme catalyzing the transfer of mono-ADP-ribose, but has not been 
investigated in more detail.  
 
Here a protein microarray-based substrate-screen is presented, not only for ARTD10 substrates but 
also for ARTD8 substrates. The results are validated and analyzed. To characterize the functional 
consequences of mono-ADP-ribosylation, GSK3β is used as prototype substrate. We could show that 
mono-ADP-ribosylation of GSK3β inhibits kinase activity in vitro as well as in cells. Moreover, we 
identified MDO2 as ADP-ribosylhydrolase capable of removing ADP-ribose from both ARTD10 itself 
and GSK3β, which suffices to restore kinase activity. The interaction between ARTD10 and GSK3β 
was addressed by bioinformatical modeling studies and GSK3β was identified as kinase of ARTD10 
in vitro. Lastly, we investigated methods to identify ADP-ribosylation sites by mass spectrometry and 
by peptide arrays, for which the currently employed methods are summarized in the introduction. 
 
This study implies that mono-ADP-ribosylating enzymes are highly specific, as only a small 
percentage of the 8000 proteins tested on the protein microarrays were modified. Moreover, the 
functional consequence of mono-ADP-ribosylation for a substrate protein described here has not been 
shown before for any eukaryotic intracellular mono-ADP-ribosylating enzyme and adds a new 
dimension to the known regulatory mechanisms of GSK3β. The hydrolyzing activities of MDO2 are 
also a novelty unlike any published before for the removal of mono-ADP-ribosylation and indicate 
that mono-ADP-ribosylation is a dynamic posttranslational modification. Together, these findings 
provide a basis for future research addressing the physiological relevance of mono-ADP-ribosylation 
in eukaryotic cells. 
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Zusammenfassung 
Posttranslationale Modifikationen spielen in fast allen zellulären Prozessen eine zentrale Rolle. Im 
Gegensatz zu Phosphorylierung und Ubiquitinierung, die bereits exzessiv untersucht wurden, ist über 
Mono-ADP-Ribosylierung nicht viel bekannt. Mono-ADP-ribosylierende Enzyme übertragen einen 
ADP-Ribose-Rest des Cofaktors NAD
+
 auf ein Zielprotein. Ein solches Enzym ist ARTD10. Doch 
genau wie über Mono-ADP-Ribosylierung selbst, ist das Wissen über dieses katalysierende Enzym 
begrenzt. 
 
In dieser Arbeit werden zwei Microarray-basierte Substrat-Screens präsentiert, sowohl für ARTD10 
als auch für ARTD8. Die Ergebnisse dieser Untersuchungen wurden validiert und analysiert, wobei 
GSK3β als Prototyp-Substrat für die Charakterisierung der funktionalen Konsequenzen von Mono-
ADP-Ribosylierung diente. Wir konnten zeigen, dass Mono-ADP-Ribosylierung von GSK3β dessen 
Kinase-Aktivität sowohl in vitro als auch in Zellen inhibiert. Weiterhin konnte demonstriert werden, 
dass die Entfernung der ADP-Ribose von GSK3β durch MDO2 ausreichend ist, um die Kinase-
Aktivität wieder herzustellen. Mittels in silico Modell-Simulationen wurde die Interaktion zwischen 
ARTD10 und GSK3β analysiert und ein Motiv in ARTD10 identifiziert, welches durch GSK3β in 
vitro phosphoryliert werden kann. Zuletzt haben wir auf Massenspektrometrie und Peptidarrays 
basierte Methoden untersucht, mittels derer ADP-Ribosylierungsstellen identifiziert werden sollen. 
Derzeit hierfür angewandte Methoden werden in der Einleitung zusammengefasst. 
 
Die Ergebnisse dieser Arbeit implizieren, dass Mono-ADP-Ribosylierung hoch spezifisch ist, da nur 
ein kleiner Prozentsatz der getesteten 8000 Proteine des Microarrays durch ARTD10 oder ARTD8 
modifiziert wurden. Weiterhin wurden die hier beobachteten Auswirkungen der intrazellulären Mono-
ADP-Ribosylierung eines Proteins, nämlich GSK3β, erstmalig für ein eukaryotisches ADP-
ribosylierendes Enzym beschrieben. Dadurch können die bereits bekannten Regulationsmechanismen 
für GSK3β um eine weitere Dimension ergänzt werden. Erstmalig konnte außerdem mit MDO2 ein 
Enzym identifiziert werden, dass in der Lage ist mono-ADP-Ribosylierung wieder zu entfernen, was  
eine Dynamik dieser posttranslationalen Modifikation impliziert. Zusammenfassend stellen die hier 
präsentierten Ergebnisse eine Basis für zukünftige Forschung dar, welche die physiologische Relevanz 
von Mono-ADP-Ribosylierung in eukaryotischen Zellen zum Thema hat.  
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Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Imagination is more important than knowledge. For 
knowledge is limited, whereas imagination embraces the 
entire world, stimulating progress, giving birth to evolution.” 
A. Einstein 
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Posttranslational modifications: in control of everything 
To get a first impression of the relevance of posttranslational modifications (PTMs), one can search 
PubMed for “posttranslational modification” and come up with approximately 40,000 articles. Over 
the past decades, it has become apparent that PTMs regulate basically everything that occurs in cells. 
Whether it is degradation of unwanted proteins, directing of proteins to different organelles or 
regulation of DNA accessibility, PTMs take care of it all. PTMs occur in different variants, ranging 
from the smaller ones like phosphorylation to the modification of proteins with small proteins like 
ubiquitin. Complexity is added to this system by enzymes that can selectively remove modifications or 
by proteins that contain binding modules for specific modifications. Some of the best characterized 
PTMs are described below by highlighting some exemplary enzymes for each class of PTM, although 
a lot more PTMs exist than can be discussed within the scope of this thesis.  
 
Phosphorylation performed by GSK3β 
Phosphorylation is a well-studied PTM, in which the γ-phosphate is transferred by a protein kinase 
from ATP onto a serine, threonine or tyrosine of a substrate. Glycogen synthase kinase 3β (GSK3β) 
was initially identified as the kinase phosphorylating glycogen synthase (Embi et al., 1980) and was 
shown to be serine/threonine specific. Later on it became clear that it phosphorylates multiple other 
proteins, thereby influencing a diversity of signaling networks (Cohen and Frame, 2001). A prominent 
role of GSK3β is for instance phosphorylation of β-catenin, an event that will lead to ubiquitination of 
β-catenin and its subsequent proteasomal degradation (Wu and Pan, 2010). GSK3β has been reported 
to influence processes as diverse as immunity (Beurel et al., 2010), cancer (Mills et al., 2011) and 
neuronal processes (Grimes and Jope, 2001). A closer look at the catalytic mechanism of GSK3β 
reveals a complex substrate binding pattern, in which a so-called priming phosphorylation docks into 
the priming phosphate site, upon which GSK3β is able to phosphorylate a second site (Dajani et al., 
2001; Frame et al., 2001). An example of a primed GSK3β substrate is the transcription factor MYC. 
After phosphorylation of serine 62 by ERK or CDKs, GSK3β modifies threonine 58. This will lead to 
MYC activation but also K48-linked ubiquitination and subsequent proteasomal degradation 
(Adhikary and Eilers, 2005; Vervoorts et al., 2006). There are known exceptions to the substrate 
recognition mechanism through priming phosphorylations however, as there are also descriptions of 
proteins being modified by GSK3β although not carrying a priming phosphate, such as presenilin-1 
(Twomey and McCarthy, 2006). It is not clear for some of the identified substrates whether they are 
also being modified in cells or are only in vitro substrates as reviewed in (Sutherland, 2011).  
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Figure 1 Schematic representation of the catalytic mechanism of GSK3β. Upon binding of the priming phosphate into the 
priming phosphate site, GSK3β phosphorylates a second site. Phosphorylation of serine 9 by e.g. AKT, will lead to folding of 
the N-terminus onto the catalytic site and occupation of the priming phosphorylation site, thereby inactivating GSK3β. 
Modified from (Frame and Cohen, 2001). 
 
The best-characterized GSK3β inhibitory mechanism makes use of this priming phosphorylation 
substrate recognition, as phosphorylation of serine 9 can serve as pseudo-substrate, which is 
schematically depicted in Figure 1 (Frame et al., 2001). The flexible N-terminus will fold back onto 
the kinase domain, with the phosphorylated serine 9 extending into the priming phosphate site, thereby 
preventing other substrates from being phosphorylated. Upon mitogenic stimuli, PI3K is activated, 
which in turn activates Akt/PKB, leading to serine 9 phosphorylation of GSK3β (Cross et al., 1995). 
Other GSK3β inhibitory mechanisms are indirect, as is for example the case in Wnt signaling. GSK3β 
is normally present in the β-catenin destruction complex, containing amongst others Axin, GSK3β and 
β-catenin, where GSK3β phosphorylates β-catenin upon priming phosphorylation by CKI (Amit et al., 
2002), leading to its subsequent ubiquitination and degradation by the 26S proteasome. Upon binding 
of Wnt to its receptors, Axin and GSK3β are recruited there to phosphorylate several other proteins 
and thus β-catenin is free to translocate into the nucleus, as reviewed in (Wu and Pan, 2010). 
 
Moreover, diverse phosphatases have been discovered that are able to remove the phosphate groups 
again, making phosphorylation a highly dynamic PTM. An example thereof is the necessity of 
dephosphorylation of the C-terminal domain of RNA Pol II at transcription termination to allow RNA 
Pol II recruitment to a new pre-initiation complex as summarized in (Moorhead et al., 2007). Research 
of phosphorylation has evolved quite far, with first papers mapping single modification sites being hot 
topics but nowadays complete phosphoproteome analysis using mass spectrometric methods such as 
SILAC is becoming more common (Mann, 2006). Several other tools exist that facilitate the study of 
phosphorylation, such as [
32
P]-γ-ATP or phospho-specific antibodies. 
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The importance of phosphorylation for normal cellular physiology is underlined by a number of 
diseases that have been linked to disturbed phosphorylation in one way or another. In chronic myeloid 
leukemia for instance, the tyrosine kinase ABL is often reported hyperactive, caused by fusion of the 
Abl1 gene to the breakpoint cluster region on the so-called Philadelphia chromosome, leading to the 
production of a BCR-ABL fusion protein (Melo, 1996) The pharmaceutical industry has implemented 
this knowledge and has developed a specific inhibitor for BCR-ABL, Gleevec and follow-up 
substances such as dasatinib, which is successfully being employed in the clinic (Cook et al., 2002; 
Sawyers et al., 2002). Adaptation of cancer cells, often by acquiring a point mutation in the ATP 
binding site in ABL and consequentially resistance against the therapies, are occurring frequently 
(Radich et al., 2006). 
 
Ubiquitination by SCF
FBW7
 
The ubiquitination system seems to be even more complex than phosphorylation, considering the fact 
that at least 3 enzymes are involved in the attachment of ubiquitin to target proteins. The E1 enzyme, 
also known as ubiquitin-activating enzyme (UBA), activates ubiquitin by binding it to its active site 
cysteine, a process that uses ATP. The activated ubiquitin is subsequently transferred to the cysteine of 
an E2 enzyme, alternatively called ubiquitin-conjugating enzyme (UBC). Finally, the E2 will bind an 
E3 ligase to transfer the ubiquitin onto a substrate (Figure 2)(Hershko and Ciechanover, 1998). 4 
major classes of E3s exist, the HECT, RING-finger, U-box and PhD-finger types, with a further 
subdivision of the RING-finger type ligases as reviewed in (Nakayama and Nakayama, 2006). 
 
 
Figure 2 Representation of the ubiquitin conjugation system. An E1-enzyme activates ubiquitin and transfers it to an E2-
enzyme. The E2 ubiquitin-conjugating enzyme will then transfer ubiquitin to a target protein assisted by the E3 ligase. This 
leads to diverse functional consequences such as degradation or recruitment of other proteins. Modified from (Vucic et al., 
2011). 
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Ubiquitin is a small protein of 76 amino acids and was discovered in 1975 by later Chemistry Nobel 
Prize winners Hershko, Ciechanover and Rose, reviewed in (Hershko and Ciechanover, 1998). It has 
long been thought that ubiquitin can only be linked through lysine 48 of ubiquitin, with the typical 
consequence of substrate protein degradation (Figure 2). Later on it became clear that ubiquitin chains 
linked via lysine 63 do not lead to protein degradation, but have been reported to regulate protein-
protein interactions and protein trafficking (Chen and Sun, 2009). Nowadays it is believed that all 7 
lysine residues present in ubiquitin can be used to build chains, as for example demonstrated by mass 
spectrometry (Xu et al., 2009). It is however not clear yet which roles the diverse ubiquitin linkages 
may have. Ubiquitin is a dynamic PTM, because deubiquitinating enzymes exist that can remove the 
ubiquitin chains (Figure 2). Ubiquitination is thought to be highly regulated, both spatially and 
temporally (Grabbe et al., 2011), partially also by ubiquitination of essential components (Weissman 
et al., 2011). 
 
It has previously been suggested that the E3 ligases are responsible for substrate specificity on their 
own, but it has become clear that they often work together with their E2 enzymes or even larger 
complexes, sometimes needing a specific “priming” phosphorylation or other PTMs to recognize a 
substrate, such as the WWE-domain containing E3 ligase Iduna/RNF146 that was reported to bind to 
poly-ADP-ribosylated Axin only, upon which Axin gets ubiquitinated with K48-linked ubiquitin and 
degraded (Zhang et al., 2011). Another example of E3 ligases with peculiar substrate specificity is 
formed by the SCF complex ligases. As depicted in Figure 3A, multiple components are responsible 
for substrate modification (Welcker and Clurman, 2008). 
 
  
Figure 3 Modification of proteins by the SCF ubiquitin ligases. (A) Multiple complex-components work together for 
substrate modification by SCF E3-ligase complexes. (B) Representation of the modification of Cyclin E by SCFFBW7, where 
SCFFBW7 recognizes a specific phospho-epitope. Modified from (Welcker and Clurman, 2008). 
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The F-box protein is the substrate-recognition part of the SKP1-Cul1-RBX1 (SCF) complex. RBX1 
binds to the UBC, previously loaded with ubiquitin, and modifies the substrate protein. FBW7 
however also binds to the substrate, bringing it into the right spatial conformation for modification to 
take place. The K48-linked ubiquitination performed by this complex leads to subsequent proteasomal 
degradation of the target proteins. Especially interesting about FBW7 is the so-called Cdc4-
phosphodegron (CDP) that it recognizes, which contains two phosphorylated residues 4 spaces apart 
(Orlicky et al., 2003). Cdc4 is the budding yeast homolog of FWB7 and was reported to recognize a 
conserved phospho-epitope on its substrates. This recognition preference links FBW7 activity to 
GSK3β activity (Figure 3B). Because GSK3β usually needs a priming phosphate, the primed sites 
modified by GSK3β will form a FBW7 recognition epitope (Welcker et al., 2004). In a way this makes 
sense, because GSK3β activity is high in absence of mitogenic signaling. Cells thus downregulate 
proteins important for proliferation such as MYC (Welcker et al., 2004), which is an obvious response 
to an environment with low mitogenic stimuli. This mechanism provides an interesting crosstalk 
between phosphorylation and ubiquitination. Because of its ability to control several proto-oncogenes, 
FBW7 has become known as a tumor suppressor that is indeed deregulated in certain tumors (Minella 
and Clurman, 2005). Other diseases, such as Alzheimer’s (Riederer et al., 2011), have also been linked 
to disruptions in the ubiquitin conjugation system, indicating that a correct functioning ubiquitin 
system is essential for normal cellular homeostasis. 
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ADP-ribosylation 
ADP-ribosylation is a posttranslational modification where, as the name already implies, ADP-ribose 
is attached to substrate proteins. In this process, β-NAD+ is used as co-factor by ADP-
ribosyltransferases that attach ADP-ribose onto an amino acid side chain of a substrate, thereby 
releasing nicotinamid (NAM) (Hassa et al., 2006). Alternatively, ADP-ribose can be transferred onto 
an acetyl group to generate free O-acetyl-ADP-ribose. This takes place during the deacetylation of 
lysines by enzymes of the SIRT family of β-NAD+-dependent deacetylases (Denu, 2005; Tong and 
Denu, 2010; Zhao et al., 2004). β-NAD+ is however probably best known for its role as cofactor in 
several other processes such as redox reactions and as cyclic ADP-ribose precursor as reviewed in 
(Magni et al., 2004; Massudi et al., 2012; Ziegler, 2000). One should thus keep in mind that through 
ADP-ribosylation not only the modified proteins are influenced, but that a link exists to a multitude of 
other processes that might also be influenced upon activation of ADP-ribosyltransferases. The 
intracellular β-NAD+ concentration is estimated to be around 500 μM (Dolle et al., 2010), extracellular 
β-NAD+ levels in human plasma are estimated to be in the 50-60 nM range (Zocchi et al., 1999). 
Extracellular NAD
+
 has long been thought to originate from dying cells, but it has been shown that 
there are also channels that can transport NAD
+
 across the membrane of viable cells (Bruzzone et al., 
2001). The role of extracellular NAD
+
 is not entirely clear yet although it has been reported to have an 
immune modulating role as reviewed in (Haag et al., 2007).  
 
The ARTC family of proteins, where the abbreviation ARTC is derived from ADP-ribosyltransferase 
cholera toxin-like, encompasses membrane-bound extracellular mono-ADP-ribosyltransferases that 
mono-ADP-ribosylate other membrane-bound proteins or secreted factors (Hottiger et al., 2010). It 
was for example reported that ARTC2 mono-ADP-ribosylates an arginine of P2X7 (Seman et al., 
2003), which is the initiation of a series of signaling events culminating in apoptosis. This was 
described as the cause for NAD
+
-induced cell death (NICD) (Koch-Nolte et al., 2006). Interestingly, 
ARTC2 can be released from activated T-cells mediated by metallo-proteases, a process during which 
ARTC2 retains activity (Kahl et al., 2000). It is currently unknown whether the secreted enzyme could 
also be taken up again by neighboring cells, akin to the mechanism used by some bacterial toxins. 
Intracellular ADP-ribosylation is performed by ADP-ribosyltransferases of the ARTD protein family. 
 
The ARTD family 
Eukaryotic intracellular ADP-ribosylation is carried out by enzymes of the ARTD family, identified 
based on the characteristic ADP-ribosyltransferase (ART) domain they all contain (Schreiber et al., 
2006). Formerly known as the PARP family, the nomenclature has recently been changed to better fit 
their mechanism of catalysis (Hottiger et al., 2010) as explained in more detail below. This protein 
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superfamily can be further subdivided based on diverse criteria. One of the major differences between 
the enzymes is the type of ADP-ribosylation performed. Class I enzymes are capable of forming poly-
ADP-ribose (PAR)-chains on their substrates, whereas class II enzymes can transfer mono-ADP-
ribose only and members of class III have no reported transferase activity at all (Kleine et al., 2008). 
 
 
Figure 4 Summary of the ARTD family of enzymes. Schematic representation of the ARTD superfamily with previous 
protein names given in brackets. Depicted domains are: ART: ADP-ribosyltransferase; PRD: PARP regulatory domain; 
WGR domain: conserved central motif W-G-R; BRCT: BRCA1 carboxy-terminal domain; AMD: automodification domain; 
ZF: zinc finger; ZF/THP: zinc finger/TiPARP homologous domain; SAP: SAF/Acinus/PIAS DNA-binding domain; RRM: 
RNA recognition motif; SAM: sterile alpha motif; ARD: ankyrin repeat domain; HPS: histidine-proline-serine region; VIT: 
vault protein inter-alpha-trypsin domain; vWA: von Willebrand type A domain; MVP-ID: Major-vault particle interaction 
domain; A1pp/macro: A1pp or macrodomain; WWE: conserved residues W-W-E; UIM: ubiquitin interaction motif; GRD: 
glycine-rich domain; CBD: central binding domain; TMD: trans-membrane domain. Depicted in black within the ART-
domains are the catalytic glutamates of ARTD1-6. Modified from (Hottiger et al., 2010). 
 
The schematic representation in Figure 4 of the proteins within the ARTD family shows that a 
multitude of different domains are present. Ranging from ADP-ribose interaction modules like the 
WWE-domains to DNA interaction motifs like the zinc fingers to ubiquitin interaction motifs in 
ARTD10. Thus outside of the catalytic domain these enzymes are highly dissimilar. This is also 
reflected in the different pathways that are influenced by the different ARTD enzymes as exemplified 
in the following. 
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ARTD1, formerly known as PARP1, is the founding member of this protein superfamily and has thus 
been studied most extensively. It is renowned for its role in DNA damage repair, but also in 
controlling chromatin and transcription (Hassa et al., 2006; Krishnakumar and Kraus, 2010). In 
addition to ARTD1, ARTD2 also participates in DNA repair and Artd1/Artd2 double knockout 
animals do not survive (Menissier de Murcia et al., 2003; Schreiber et al., 2002). In BRCA1-negative 
breast cancer, tumor cells rely on ARTD1 for DNA damage repair (Ashworth, 2008). This is being 
utilized in the clinic, where ARTD1 is inhibited with for example olaparib, leading to death of the 
cancer cells specifically, an effect that is enhanced when used in combination with DNA-damaging 
agents such as cisplatin (Jagtap and Szabo, 2005). These therapies are currently being extended to 
other cancers as well, hinting at the possible future possibilities of ARTD inhibitors (Javle and Curtin, 
2011; Sandhu et al., 2011). Moreover, additional compounds inhibiting not only ARTD1, but targeting 
for example also ARTD5 are currently being developed (Wahlberg et al., 2012). ARTD1 has also been 
suggested to function in other signaling networks such as NF-κB signaling and apoptosis, although the 
molecular mechanisms remain largely unclear (Hassa and Hottiger, 2002; Schreiber et al., 2006). Not 
only ARTD1 has been implicated in immunity, but for example ARTD13 as well (Welsby et al., 
2012). 
 
The role of ARTD5 in Wnt-signaling was identified quite recently. It was shown that ARTD5 
synthesizes PAR chains on Axin, leading to its degradation and subsequent increased β-catenin 
signaling (Huang et al., 2009) as usually happens upon activation of Wnt signaling through spatial 
regulation of GSK3β and Axin (McNeill and Woodgett, 2010). By employing a synthetic compound, 
XAV939, ARTD5 was inhibited in this study, leading to Axin-stabilization and subsequent reduced 
Wnt-signaling. Later on, Iduna was identified as E3 ubiquitin ligase binding to the PAR chains on 
Axin. Ubiquitination of Axin by Iduna then targets Axin for degradation (Zhang et al., 2011). 
Previously, ARTD5 and ARTD6 were identified as interaction partner of TRF1, a negative regulator 
of telomerase, which inhibits telomerase function (Cook et al., 2002; Smith et al., 1998). 
Phosphorylation of ARTD5 by polo-like kinase 1 (PLK1) stabilizes ARTD5, thereby increasing 
telomeric ART activity (Ha et al., 2012). Additionally, ARTD5 and ARTD6 control the stability of the 
adaptor 3BP2, mutations of which are mechanistically linked to Cherubism, a syndrome characterized 
by progressive loss of bone in the jaws and accumulation of inflammatory tissue (Guettler et al., 2011; 
Levaot et al., 2011). ARTD6 binds to 3BP2 through its ankyrin repeat and a targeting sequence in 
3BP2 and poly-ADP-ribosylates it (Figure 5). This leads to subsequent poly-ubiquitination by Iduna 
and proteasomal degradation. In Cherubism, the targeting sequence within 3BP2 is mutated and thus 
not recognized by ARTD6. The known functions of poly-ADP-ribosylation have recently been 
summarized, however the final conclusion drawn states that a lot of essential information is still 
lacking, such as a better knowledge of the intracellular targets and how they vary under different 
physiological conditions (Gibson and Kraus, 2012). 
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Figure 5 Consequences of modification of 3BP2 by ARTD6. ARTD6 (formerly Tankyrase 2) recognizes the recognition 
peptide present in 3BP2 and poly-ADP-ribosylates 3BP2, leading to its poly-ubiquitination by Iduna and subsequent 
proteasomal degradation. In Cherubism, the recognition sequence of 3BP2 is mutated and thus the protein is not ADP-
ribosylated and becomes stabilized. Modified from (Gibson and Kraus, 2012). 
 
ARTD7, -8 and -9, formerly BAL1, -2 and -3, or PARP9, PARP14 and PARP15, have been identified 
as risk factors in diffuse large B-cell lymphoma (Aguiar et al., 2005; Aguiar et al., 2000). They are 
unique within the ARTD family because of the macrodomains they share. ARTD9 lacks catalytic 
activity due to a change in the catalytic triad from H-Y-E in ARTD1 to Q-Y-T (Kleine et al., 2008), as 
described in more detail below, but has been shown to repress transcription in reporter gene assays, 
dependent on its macrodomains (Aguiar et al., 2005). ARTD9 shares a promoter with the E3-ligase B-
cell aggressive lymphoma and BAL1 binding partner (BBAP) that is inducible by IFNγ, moreover it 
could be shown that the synthesized proteins shuttle into the cytoplasm together, most likely driven by 
an NES in BBAP (Juszczynski et al., 2006). Lymphoma cells transfected with ARTD7 upregulate 
several interferon-stimulated genes (ISGs) (Juszczynski et al., 2006). In support of a role for ARTD7-
9 in lymphomagenesis is the proposed role of ARTD8 in IL-4 induced survival signaling, although it 
is not clear yet whether catalytic activity is necessary for ARTD8s capacity to regulate cellular 
metabolic rates and enhance glycolysis (Cho et al., 2011; Cho et al., 2009). ARTD8 actually has 
originally been identified as factor potentiating STAT6 mediated transcription and has accordingly 
been named co-activator of Stat6 (CoaSt6) in earlier studies (Goenka and Boothby, 2006). This seems 
to contradict the function of ARTD9 although the activation of STAT6-mediated transcription by 
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ARTD8 is no general effect since ARTD8 does not stimulate IFNγ-induced transcription (Goenka et 
al., 2007). ARTD8 has also been linked to gastric and colorectal cancers, because frame-shift 
mutations were found in the ARTD8 gene in tumors with high microsatellite instability, that lead to a 
protein with intact macrodomains but lacking catalytic activity (Kim et al., 2011). 
 
IFNs have also been linked to ARTD12, formerly known as PARP12 or ZC3HDC1. In a study of 
alphavirae, a noncytopathic Venezuelan equine encephalitis virus (VEEV) mutant was employed that 
is able to replicate in cells lacking IFN production (Atasheva et al., 2012)the.  One of the genes that 
are upregulated during VEEV infection is the long isoform of ARTD12. ARTD12 exhibits an 
inhibitory effect on the replication of VEEV as well as on other alpha- and RNA viruses in this study 
(Atasheva et al., 2012). These findings are in accordance with an earlier publication wherein the role 
of ISGs was investigated and ARTD12 was found to counteract HCV infectivity (Schoggins et al., 
2011), although only mentioned in the supplementary tables and not investigated mechanistically. 
These findings hint at a function for ARTD12 in viral immunity, although both papers are mainly 
descriptive and do not address whether for example catalytic activity is needed.  
 
ARTD13, formerly known as ZAP or ZC3HAV1, is one of the ARTDs that lack catalytic activity 
(Kleine et al., 2008). Nevertheless, also for ARTD13 a role has been proposed in virus immunity, 
hence the name zinc-finger antiviral protein (ZAP). It was identified in a study wherein cells were 
transduced with retrovirus, followed by selection of virus-resistant clones. An antiviral cDNA was 
recovered, coding for ARTD13. Overexpression of ARTD13 leads to a loss of viral RNAs from the 
cytoplasm, indicating that ARTD13 is involved in antiviral immunity (Gao et al., 2002). ARTD13 
gene expression is induced upon viral infection in an IRF3-dependent manner (Wang et al., 2010). The 
long isoform of ARTD13 contains not only the ART domain, but also a WWE-domain and a CCCH 
zinc finger-containing domain, which it shares with ARTD14 (formerly PARP7 or TiPARP) and 
ARTD8 (Schreiber et al., 2006). The function of ARTD14 is also not clear yet, although it has been 
implicated in T-cell functions and contributes to tumor promotion upon its induction by 2, 3, 7, 8-
tetrachlorodibenzo-p-dioxin (Ma et al., 2001). Mechanistically, the function of ARTD13 in virus 
immunity has been better investigated than the roles of the other mono-ARTDs described above. 
Through its zinc-fingers, ARTD13 binds to a broad range of different viruses as first described for the 
3’LTR of the Moloney murine leukaemia virus (MMLV) and for a sequence in the genome of the 
alphavirus Sindbis (SINV) (Guo et al., 2004). Here it could also be shown that binding of RNAs is 
mainly mediated by zinc finger 2 and 4. The different viruses that ARTD13 can bind to are reviewed 
in (Welsby et al., 2012). ARTD13 interacts with the p72 DEAD box RNA helicase (DDX17), which is 
required for ARTD13-mediated RNA degradation (Chen et al., 2008) and although ARTD13 is 
inactive (Kleine et al., 2008), the longer isoform containing the ARTD domain displays an enhanced 
suppression of viruses (Kerns et al., 2008). ARTD13 binds to the RNA helicase RIG-I through its zinc 
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finger domain upon stimulation with 5’-triphosphate modified RNA (Hayakawa et al., 2011). This 
triggers RIG-I ATPase activity and oligomerization, which are both necessary for induction of NF-κB 
activity. Accordingly, downregulation of ARTD13 reduced the response to influenza and Newcastle 
Disease virus infection (Hayakawa et al., 2011). Multiple reports indicate that ARTD13 synergizes 
with diverse ISGs to inhibit alphavirae, which could be a starting point for future studies to further 
define the underlying mechanism (Karki et al., 2012; MacDonald et al., 2007). Phosphorylation of 
ARTD13 by GSK3β is suggested to enhance antiviral activity (Sun et al., 2012). Together, these 
reports indeed support a role of the mono-ARTDs in viral immunity, perhaps even independently of 
ART activity as in the case of ARTD13. 
 
The only report on the function of ARTD15 states that it interacts with and modifies karyopherin-β1, 
although it remains open what the consequence of mono-ADP-ribosylation is for the function of 
karyopherin-β (Di Paola et al., 2012). Additionally, the modification site within karyopherin- β is not 
investigated. The crystal structure of ARTD15 reveals that there is an α-helical domain next to the 
ART domain that does not resemble the regulatory domain of ARTD1, which was proposed to be 
important for ARTD15 regulation (Karlberg et al., 2012). 
 
An interesting observation is that most of the functions unraveled so far for PAR chains depend on the 
recruitment of other proteins to those PAR chains, such as the E3 ubiquitin ligase Iduna, but have 
mostly not been reported to directly influence the proteins these chains are synthesized on. These 
reports show that the ARTDs are not only involved in DNA damage repair, but have diverse functions 
to fulfill as already suggested by the multitude of domains present in the different members. 
Unfortunately, most of the ARTD family members are currently poorly understood, especially the 
mono-ADP-ribosyltransferases such as ARTD10. The data on roles of the mono-ARTDs in 
intracellular pathways are very limited and mainly descriptive; the underlying mechanisms remain to 
be uncovered in future investigations.  
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ARTD10: a mono-ADP-ribosyltransferase 
The mono-ADP-ribosylating enzyme that is currently characterized best, is the enzyme that is 
nowadays called ARTD10 (Hottiger et al., 2010). ARTD10 was known under a different name in the 
early days, namely p150. The reason for this name was an experiment, in which “p150” was identified 
as an interaction partner of the proto-oncoprotein MYC (Yu et al., 2005). It was reported that 
ARTD10 undergoes automodification and is able to modify core histones, but it could not be shown to 
modify MYC or its binding partner Max in this study. Independent of enzymatic activity, ARTD10 is 
capable of inhibiting MYC and E1A mediated co-transformation of rat fibroblasts, indicating a role for 
ARTD10 in proliferation. In support of a role of ARTD10 in proliferation is the finding that 
knockdown of ARTD10 using siRNA also leads to a disturbed cell cycle and disturbed proliferation 
rates (Chou et al., 2006). ARTD10 can be distinguished from the other ARTDs based on protein 
architecture (Schreiber et al., 2006).  
 
 
Figure 6 ART10 domain architecture. The domains that have been identified so far in ARTD10 are displayed, numbers 
indicate amino acids of human ARTD10. RRM: RNA recognition motif; G-rich: glycine rich region; E-rich: glutamate rich 
region; NES: nuclear export signal; UIM: ubiquitin interaction motif. 
 
Apart from the characteristic catalytic domain, ARTD10 contains an RNA recognition motif, two 
ubiquitin interacting motifs, a nuclear export sequence, a glycine-rich region and a glutamate-rich 
region (Figure 6). None of these domains have been investigated in more detail as yet, apart from the 
nuclear export sequence and the catalytic domain, so it is not clear currently which functions they 
mediate. Detailed investigations of the catalytic mechanism of ARTD10 revealed that, in contrast to 
its name at the time, poly-ADP-ribose polymerase 10, ARTD10 is capable of transferring only one 
ADP-ribose moiety (Kleine et al., 2008). The loop connecting β-strands 4 and 5 is shorter in ARTD10 
than in the poly-ARTDs, which is proposed to account for a higher substrate specificity of ARTD10 
than for example ARTD1. ARTD10 shares this short loop with the other mono-ARTDs (Kleine et al., 
2008). 
 
Investigation of different cell lines has shown that ARTD10 is highest expressed in hematopoietic 
tissues, although RNA transcripts were found in a broad range of cell types (Yu et al., 2005). ARTD10 
is a cytoplasmic protein and shuttles out of the nucleus in a Crm1-dependent manner (Yu et al., 2005). 
These findings were further validated and expanded by studying overexpressed protein, that localizes 
to cytoplasmic bodies of unknown nature that are highly dynamic and wherein ARTD10 colocalizes 
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with p62 and poly-ubiquitin (Kleine et al., 2012). p62 is an ubiquitin-binding adaptor protein targeting 
ubiquitinated proteins for degradation by autophagy (Johansen and Lamark, 2011), but it remains 
unclear whether ARTD10 has an active role to play in autophagy or whether it is being degraded itself 
through autophagy. ARTD10 could for example be ubiquitinated itself and targeted to the 
autophagosomes, it could however also bind to ubiquitinated proteins through its UIMs and deliver 
those to the autophagosomes. Moreover, it is currently unknown whether certain stimuli such as stress 
or mitogens can induce localization of ARTD10 to different structures. 
 
Another study identified ARTD10 as protein interacting with an avian influenza virus non-structural 
protein, NS1 (Yu et al., 2011). The region of interaction was mapped to both the glutamate-rich region 
and the catalytic domain of ARTD10. Overexpression of NS1 not only led to accumulation of 
ARTD10 in the nucleus, but also to a downregulation of endogenous ARTD10. Lastly, it was shown 
that apparently combined NS1 overexpression and knockdown of ARTD10 lead to an increase of cells 
in the G2-M phase of the cell cycle from 10% in controls cells to 45% in NS1 
overexpressing/ARTD10 knockdown cells. NS1 overexpression or ARTD10 knockdown alone could 
not produce this effect (Yu et al., 2011). In a study where the antiviral properties of ARTD12 where 
analyzed, ARTD10 could also be identified as ARTD that inhibits VEEV replication, although not as 
efficiently as ARTD12 or ARTD7. The authors postulate that this might be due to RNA binding 
through the zinc fingers in ARTD7 and ARTD12 and the RRM in ARTD10 (Atasheva et al., 2012), 
although they do not follow up on this hypothesis in the current publication. 
 
The posttranslational regulation of ARTD10 has been investigated in only one publication so far. 
Chou and colleagues identified a phosphorylation site in ARTD10, threonine 101, which is 
phosphorylated by cyclin E/CDK2. The phosphorylated form of ARTD10 could only be detected in 
the nucleus in late G1 to S-phase of the cell cycle (Chou et al., 2006). In in vitro assays, 
phosphorylated ARTD10 possesses higher catalytic activity (Chou et al., 2006). The influence of 
phosphorylation on threonine 101 on catalytic activity could not be reproduced however (H. Kleine, 
unpublished data). Moreover, a colocalization with RNA Pol II during mitosis could be noted. This 
phosphorylation disappears in growth-arrested cells (Chou et al., 2006). The same authors also 
knocked down ARTD10 mRNA using shRNA, which led to a decrease in cell number. This indicates 
that tightly regulated ARTD10 levels are vital for normal cell physiology, as it was shown before that 
overexpression of ARTD10 also leads to decreased cell numbers in colony formation assays (Kleine et 
al., 2008). 
 
Several other studies however have found the ARTD10 mRNA level up- or downregulated under 
certain experimental conditions. Upon treatment of peripheral blood mononuclear cells with live 
Borrelia burgdorpheri, but not borrelial lysates, ARTD10 mRNA was found to be upregulated, as well 
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as ARTD8 mRNA (Salazar et al., 2009). In sooty mangabeys ARTD10 mRNA was reported 
upregulated 7 days after infection with simian immunodeficiency virus (SIV), together with an 
upregulation of ARTD8, ARTD9 and ARTD11 mRNA (Bosinger et al., 2009). By using whole-genome 
microarrays and subsequent promoter reporter gene constructs, ARTD10 was identified as gene 
upregulated by interferon-α (IFNα) treatment. ARTD10 was one of the genes upregulated after 16 
hours of treatment but not after 6 hours, which makes it part of a late response. This late response hints 
at an as yet unidentified indirect regulatory mechanism. The same study also identified the Newcastle 
disease virus (NDV) as potent ARTD10 mRNA inducing agent, in contrast to several other tested 
DNA and RNA viruses that could not induce ARTD10 mRNA upregulation (Mahmoud et al., 2011). 
ARTD10 and ARTD12 were both reported to belong to the proteins present in red blood cells 
(D'Alessandro et al., 2010). On the contrary, ARTD10 mRNA was downregulated in THP-1 
macrophages treated with oxidized low-density lipoprotein (Kang et al., 2009). Additionally, 
knockdown of ARTD10 in primary hepatocytes leads to decreased apoliprotein B levels (Shen et al., 
2012), both articles thus linking ARTD10 to lipid metabolism. Transcriptome analysis in bovine 
endometrium revealed ARTD10 as gene differentially regulated during the estrous cycle (Bauersachs 
et al., 2008; Mitko et al., 2008). Finally, ARTD10 is one of the genes upregulated in invasive 
functional pituitary adenomas but not in non-invasive pituitary adenomas (Galland et al., 2010). Since 
these studies were not aimed at investigating ARTD10 specifically, it remains open how up- or 
downregulation of ARTD10 mRNA was achieved under the circumstances tested, moreover most of 
these data need to be validated. These findings suggest that ARTD10 might not only have a role to 
fulfill in the immune response, as has been suggested previously for several other mono-ARTDs, but 
also in lipid metabolism and possibly fertility and cancer. 
 
The transcriptional regulation of ARTD10 expression has not been studied so far, apart from the 
above-mentioned study that identified IFNα as cytokine indirectly inducing ARTD10 expression. The 
ARTD10 gene has been mapped to the same chromosome as the MYC gene, at the tip of the long arm 
of chromosome 24 (8q24) (Yu et al., 2005). The murine Artd10 gene was analyzed in more detail and 
was described to share its most 3’- exons, exon 10 and 11 with the neighboring gene, Plectin1. 
Moreover it was proposed that intron 9 of Artd10 contains a promoter of the Plectin1 gene. Although 
the murine gene was studied, the described overlap with Plectin1 is also present in rat and human 
genomes. Lastly, conservation throughout the species was studied. The ARTD10 gene was found in 
multiple vertebrates, but not in any invertebrates, indicating that ARTD10 has evolved in the 
vertebrate lineage (Lesniewicz et al., 2005). It has not been studied yet how the ARTD10 promoter is 
regulated or whether the overlap with the PLECTIN1 gene has further consequences. The ARTD10 
protein however has been utilized as proto-type mono-ADP-ribosyltransferase to investigate the 
catalytic mechanism employed by these enzymes in more detail. 
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Mechanistic insights into ADP-ribosylation 
The functional consequence and molecular mechanism of ADP-ribosylation, is currently best 
understood not for eukaryotic ADP-ribosylation, but for prokaryotic ADP-ribosylation. Pertussis 
toxin, produced by Bordetella pertussis, exists of 5 subunits and can be taken up by target cells 
through receptor-mediated endocytosis. The enzymatically active S1 subunit modifies the α-subunit of 
trimeric G proteins in cells, leading to a disturbance of cellular processes as reviewed in (Locht et al., 
2011). The first toxin that was identified as ADP-ribosyltransferase is diphtheria toxin, a secreted 
protein produced by the bacterium Corynebacterium diphtheriae. The protein can be divided in three 
domains, a catalytic, a translocation and a receptor-binding domain. Through the receptor-binding 
domain, it can bind to and enter most human cell types. Required for activity is cleavage of the toxin 
in an endosomal compartment, releasing the N-terminal catalytic domain into the cytosol aided by its 
translocation domain (Collier, 2001). Inside the cells, diphtheria toxin mono-ADP-ribosylates 
eukaryotic elongation factor 2 (eEF2) (Webb et al., 2008). ADP-ribosylation disturbs its association 
with other proteins and thus blocks protein synthesis. 
 
The bacterial endotoxins can be subdivided into two different subclasses based on the amino acids in 
their catalytic center that are involved in catalysis (Hottiger et al., 2010). The first group contains a 
histidine, tyrosine and glutamate (H-Y-E) residue that interact with the NAD
+
-moiety, the second 
group contains an arginine, serine and glutamate (R-S-E) that are necessary for NAD
+
-binding (Figure 
7). Amongst others, diphtheria toxin belongs to the first class while pertussis toxin belongs to the 
second class. Toxins of the H-Y-E class have been demonstrated to modify glutamate residues 
whereas toxins of the R-S-E class modify arginine residues. Based on this, the eukaryotic ADP-
ribosylating enzymes were also subdivided: the ARTC class for ADP-ribosyltransferase cholera toxin-
like and the ARTD enzymes, the ADP-ribosyltransferases diphtheria toxin-like, with corresponding 
catalytic triad (Hottiger et al., 2010). 
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Figure 7 Structural alignments of the conserved elements of ADP-ribosyl transfering catalytic domains. Category I 
contains the poly-ADP-ribosylating enzymes, exemplified by a comparison of ARTD1 with diphteria toxin. Category II are 
the mono-ADP-ribosylating enzymes, where ARTD10 is compared with tRNA phosphotransferase. Category III enzymes are 
the ecto-ADP-ribosylating enzymes, where ARTC2 compared with C3 exotoxin. In III, the interaction of NAD+ with the 
residues of the H-Y-E and R-S-E motifs are displayed schematically, with interacting residues labeled in red. Modified from 
(Hottiger et al., 2010). 
 
Eukaryotic intracellular poly-ADP-ribosylation was first described in 1963 (Chambon et al., 1963), 
subsequently its crystal structure was solved and finally, more than 20 years after the initial discovery 
of PAR, the gene for ARTD1 was identified as reviewed in (D'Amours et al., 1999). Nowadays, 
several enzymes with ADP-ribosyltransferase activity have been identified as described above and a 
distinction has been made between enzymes that can transfer multiple ADP-ribose moieties onto a 
substrate and the ones that can transfer only one ADP-ribose (Kleine et al., 2008). The poly-ADP-
ribosylation process has been researched relatively well and can be divided into three parts, initiation, 
elongation and branching as reviewed elsewhere (Diefenbach and Burkle, 2005). As described above 
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for the bacterial toxins, the catalytic residues H-Y-E of the eukaryotic intracellular transferases are 
responsible for NAD
+
-binding and subsequent transfer of ADP-ribose onto substrates. 
 
The mono-ADP-ribosyltransferases all lack the glutamate of the H-Y-E triad that is necessary to 
support the oxacarbenium ion transition state arising during catalysis (Kleine et al., 2008). It has been 
proposed that these enzymes use a glutamate of their substrates instead to stabilize the reaction in a 
process called substrate-assisted catalysis. During this process, these glutamates not only stabilize the 
reaction, but also get modified (Figure 8).  
 
 
 
Figure 8 Representation of the catalytic mechanism of the poly-ARTDs and the mono-ARTDs. The poly-ARTDs 
contain a catalytic glutamate as represented on the left. The mono-ARTDs lack this glutamate as depicted on the right and 
were proposed to employ their substrates glutamate to stabilize the oxacarbenium ion transition state that arises during 
catalysis. This glutamate not only stabilizes the reaction in this model, but is also the ADP-ribose acceptor amino acid. 
Modified from (Kleine et al., 2008). 
 
This explains why these enzymes transfer only one ADP-ribose moiety onto substrates, because once 
the substrates glutamate has been modified, it cannot assist in catalysis anymore (Kleine et al., 2008). 
In agreement with this, in vitro assays with ARTD10 and its substrate H2B revealed glutamate 2 of the 
histone tail as modification site using mutagenesis (Moyle and Muir, 2010), although it is suggested in 
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this study that this is not the only modification site in H2B. This process has not been accepted as a 
general mechanism for all mono-ADP-ribosyltransferases of the ARTD family yet, as it was reported 
recently that ARTD15 might actually modify serines or threonines, although no direct evidence was 
provided (Di Paola et al., 2012). Furthermore it is unclear how the catalytic mechanism would 
function in a reaction wherein serine or threonine function as acceptor sites. Taking a closer look at 
the attempts to distinguish which enzyme modifies what residue by what mechanism, it becomes clear 
that this a very complicated issue with no satisfying explanation available yet. 
 
To distinguish between the different amino acids as acceptor residues, neutral hydroxylamine 
treatment has been the most prominent tool so far. Neutral hydroxylamine has been described to 
disrupt not only the ester bond between acidic residues and ADP-ribose but also the ketamine bond 
between arginine or lysine and ADP-ribose, although with different kinetics (Moss et al., 1983). ADP-
ribosylated proteins with a high susceptibility to neutral hydroxylamine treatment, with a half-life of 
about 3 minutes, are generally believed to be ester linkages between acidic residues and ADP-ribose 
whereas the half-life of arginine-ADP-ribose bonds is approximately one hour (Hsia et al., 1985). 
More stable is the bond between cysteine and ADP-ribose (Hsia et al., 1985). No eukaryotic 
intracellular enzymes have been identified so far that can ADP-ribosylate cysteines however.  
 
Early papers have hinted at the presence of both modified arginines and glutamates in histone extracts 
as determined by diverse chemical approaches, where it was also noted that mono-ADP-ribosylation is 
the major modification taking place on histones rather than poly-ADP-ribosylation (Bredehorst et al., 
1978; Burzio et al., 1979). Interestingly, a connection has been made between acetylation and ADP-
ribosylation, as it could be shown that acetylated histone H4 subspecies have increased ADP-
ribosylation compared to non-acetylated histones (Golderer and Grobner, 1991). In this report a 
distinction was also made between arginine and glutamate-linked ADP-ribosylation, which apparently 
were both present on histones in isolated nuclei from macroplasmodia (Golderer and Grobner, 1991). 
 
Contradictory reports exist concerning the amino acids that are being modified by the intracellular 
ARTD enzymes. In ARTD1, mutation of the glutamates within an ARTD1ΔBRCT construct, did not 
lead to abolished automodification, indicating that glutamic acid residues within ARTD1 at least are 
not the only acceptor sites. Moreover, since 30 minutes incubation with 1 M neutral hydroxylamine 
did not lead to release of the modification, the authors conclude that lysines or arginines are the 
acceptor sites instead of acidic residues. Upon mutation of K498, K521 and K524, automodification 
was significantly decreased, implying that these lysines are the sites automodified by ARTD1 
(Altmeyer et al., 2009). The same group also identified lysines on ARTD2 as automodification and 
acetylation sites (Haenni et al., 2008). Contradicting these findings is a report on glutamates within 
ARTD1 as automodification site (Tao et al., 2009). Concerning substrates other than automodification, 
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reports exists on the modification of histones by ARTD1, in which certain lysines could be mapped as 
modification site by using electron transfer dissociation (ETD) mass spectrometry (Messner et al., 
2010). For ARTD10, so far only glutamates have been identified as acceptor sites (Kleine et al., 2008; 
Moyle and Muir, 2010). Finally, ARTD15 supposedly modifies neither acidic nor basic residues, but 
threonine or serine instead (Di Paola et al., 2012). This was concluded since the automodification 
could not be removed by hydroxylamine treatment, nor by mercuric chloride, which would have 
disturbed an ADP-ribose-cysteine bond. Instead, the linkage seems destabilized by HCl treatment, 
which was reported before to disturb serine- or threonine-ADP ribose bonds (Cervantes-Laurean et al., 
1995). 
 
Matters are complicated by possible in vitro artifacts, in which for instance mutation of a certain site 
leads to a conformational change, in such a way that a modification site becomes covered or a binding 
surface is disturbed. This could lead to the false assumption that the mutated site is the modification 
site. Glycation, the process in which lysines can get modified non-enzymatically (Caldes et al., 2011; 
Cervantes-Laurean et al., 1996; Fedorova et al., 2010) complicates matters even further as it can lead 
to false positives. Finally, the lack of tools such as antibodies against mono-ADP-ribosylation on 
specific residues and the lack of reliable mass spectrometry methods make the identification of 
modification sites a real challenge. 
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Removing and reading ADP-ribosylation 
Current understanding of the enzymes capable of removing ADP-ribose is not as extensive as current 
knowledge on e.g. the deubiquitinating enzymes and moreover, most research is directed at poly-
ADP-ribose chains. It is for example known that poly-ADP-ribosylglycohydrolase (PARG) is capable 
of cleaving the glycosidic bond between ADP-ribose units, summarized in (Bonicalzi et al., 2005) and 
is thus unable to remove the last ADP-ribose moiety attached to substrates. PARG seems to be vital 
for development, as knock-out mice display embryonic lethality (Koh et al., 2005). However, the 
study of PARG has been complicated by the existence of multiple isoforms that display a different 
intracellular localization pattern (Haince et al., 2006; Meyer-Ficca et al., 2004). 
 
ADP-ribosylhydrolase 1-3 (ARH1-3) have different substrate preferences, ARH1 cleaves only 
linkages between arginine and ADP-ribose (Takada et al., 1993). ARH1 seems to be vital for normal 
cell proliferation, as cells from ARH1
-/-
 mice have higher proliferation rates and ARH1
+/-
 mice 
spontaneously develop different cancers (Kato et al., 2011). No studies have been made of ARH2 yet. 
ARH3 was reported to have glycohydrolase activity towards PAR-chains but does not display activity 
against bonds between ADP-ribose and arginine, cysteine, diphthamide or asparagine, similar to 
PARG (Oka et al., 2006). ARH3 however has a structure differing from PARG and could also be 
shown to hydrolyze the reaction product of the sirtuins, O-acetyl-ADP-ribose (Ono et al., 2006). 
Additionally, ARH3
-/-
 mice show reduced PAR-degradation at mitochondria, indicating that ARH3 and 
not PARG is the responsible enzyme for PAR degradation at mitochondria (Niere et al., 2012). An 
additional class of proteins with ADP-ribose hydrolase activity at least in vitro for some of the 
superfamily members, are the NUDIX proteins (McLennan, 2006). It is not clear however whether 
they degrade PAR or O-acetyl-ADP-ribose in cells.  
 
The little information available on the ADP-ribose hydrolases leaves room for speculations. It is not 
known whether there really are only so few ADP-ribosylhydrolases or whether there are other classes 
of hydrolases that remain to be discovered yet, for example enzymes that can remove ADP-ribose 
from lysine or glutamate. The very presence of intracellular arginine-ADP-ribosylhydrolases is 
actually paradoxical, since the eukaryotic arginine-modifying ARTCs modify extracellular proteins. 
Either this is some kind of protection against arginine-ADP-ribosylation by toxins or there are also 
intracellular arginine-specific ADP-ribosyltransferases that have not been discovered yet. Mice 
lacking ARH1 display a higher sensitivity towards the toxic effects of cholera toxin (Kato et al., 
2007), arguing for a role in protection against the products of bacterial toxins. It remains unknown 
how the last ADP-ribose unit attached to glutamates is removed, as has been reported to occur in 
ARTD1 and ARTD10 automodification (Kleine et al., 2008; Tao et al., 2009). The recently solved 
crystal structure of PARG (Slade et al., 2011) may provide more insight in this issue. PARG quite 
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surprisingly folds like a macrodomain, which was not expected since the protein sequence had not 
revealed the presence of a macrodomain (Hassler et al., 2011). In these structures, only the PAR 
terminus fits in the catalytic center, leading the authors to postulate that PARG has only 
exoglycohydrolase activity (Slade et al., 2011). Since the macrodomain-fold of PARG could not be 
deduced from amino acid sequence alone, it can be hypothesized that there are more proteins 
unrecognized yet that have a macrodomain fold and corresponding PARG activity. 
 
The macrodomain is an ADP-ribose binding module (Karras et al., 2005), with reported deacetylase 
activity of O-acetyl-ADP-ribose for some of macrodomain containing proteins (Chen et al., 2011; 
Peterson et al., 2011). The macrodomain containing archaeobacterial protein Af1521 from 
Archaeoglobus fulgidus was used to pull-down the ADP-ribosylated proteins from Chinese hamster 
ovary cells (Dani et al., 2009), indicating that macrodomains might become an important tool in the 
investigation of mono-ADP-ribosylation. Several of the macrodomain-containing proteins have been 
shown to bind to ADP-ribose not only in vitro but also in cells (Ahel et al., 2009; Gottschalk et al., 
2009), reviewed in (Han et al., 2011; Kleine and Luscher, 2009). It could be shown that upon DNA 
damage induced with laser-microirradiation, ARTD1 becomes poly-ADP-ribosylated and as a 
consequence diverse macrodomains are attracted to the site of damage (Timinszky et al., 2009). 
 
 
Figure 9 Representation of the binding properties of different ADP-ribose binding modules. Depicted are a substrate 
protein with in pink the (n-1) ADP-ribose and in blue the terminal ADP-ribose. The WWE domain recognizes the iso-ADP-
ribose residue, unique to PAR chains, highlighted with a blue box. The PBZ recognizes mainly the same, but can 
occasionally also bind to the distal phosphate and ADP-ribose residue, depicted with an orange box. The macrodomain binds 
to the terminal ADP-ribose residue as depicted with a green box. Modified from (Gibson and Kraus, 2012). 
 
Two more domains have been identified that interact with poly-ADP-ribose, the WWE domain, named 
after its most conserved residues (Aravind, 2001) and the poly-ADP-ribose-binding zinc finger (PBZ) 
found in DNA-repair/checkpoint proteins (Ahel et al., 2008). Proteome-wide analysis of PAR-
interacting proteins has identified another motif binding to ADP-ribose, existing of 8 amino acid 
residues (PAR-binding motif, PBM) (Gagne et al., 2008). A schematic representation of the different 
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recognition patterns of these modules is given in Figure 9. The binding specificity of PBM is not clear 
yet and therefore not depicted in this overview. What becomes clear in this figure is that the WWE 
domain and PBZ probably only recognize poly-ADP-ribose, since mono-ADP-ribosylation forms no 
ribose-ribose glycosidic bond. However, a recent NMR investigation of the WWE domains from 
Iduna and ARTD11 contradict this representation, as the WWE domain from Iduna indeed binds to 
iso-ADP-ribose according to these models but the WWE domain from ARTD11 in contrast seems to 
recognize the terminal ribose of PAR chains (He et al., 2012). The ARTD8 WWE domain seems 
unable to bind any form of ADP-ribose because the binding pocket appears to be covered by its β3 
strand. These findings led the authors to speculate that in ARTD8 the macrodomains have taken over 
this function (He et al., 2012). These findings will have to be further evaluated in future studies. 
 
An example of a protein binding to PAR chains through a WWE-domain is Iduna, which is recruited 
to ADP-ribosylated proteins or proteins that are bound to PAR and becomes active only after binding 
to ADP-ribosylation. It then ubiquitinates for example ARTD1, thereby targeting it for proteasomal 
degradation, additional Iduna substrates are amongst others XRCC-1 and KU70 (Kang et al., 2011) 
and the above described Axin (Callow et al., 2011; Zhang et al., 2011). A general mechanism of 
crosstalk between ubiquitination and ADP-ribosylation through the WWE-domain has already been 
suggested (Wang et al., 2012). 
 
Obviously, a lot of open questions remain regarding the removal of mono-ADP-ribose as well as the 
intracellular recognition of mono-ADP-ribose, as above mentioned studies mainly focus on poly-
ADP-ribosylation. The reports on proteins recognizing PAR in cells are also not numerous, implying 
that there is much to be learned on recognition of and binding to ADP-ribosylation in cells, for both 
mono-ADP-ribose and poly-ADP-ribose chains. One major hindrance that has to be overcome first is 
the lack of suitable tools to study mono-ADP-ribosylation in cells. 
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Measuring ADP-ribosylation 
Poly-ADP-ribosylation can be detected in cells, as an antibody recognizing PAR chains has been 
developed. This can be employed to detect PAR chains in Western Blots as well as in cells in 
immunofluorescence approaches, as demonstrated in several publications investigating poly-ADP-
ribosylation (Davis et al., 2012; Kang et al., 2011; Murawska et al., 2011). As described above, there 
is no consensus yet which amino acids serve as acceptor residue for which ARTD enzyme. There have 
been several attempts to create methods to solve the difficulties in the detection of ADP-ribosylation 
in cells and in the determination of acceptor sites within substrate molecules, as summarized below. 
 
Antibodies have been raised against mono-ADP-ribose linked to arginine (Eide et al., 1986; Meyer 
and Hilz, 1986; Osago et al., 2008; Schwab et al., 2000), these antibodies are however reported to 
have low specificity, as they apparently cross-react with other ADP-ribose species (Laing et al., 2011). 
Additionally, these antibodies are not commercially available and moreover, antibodies against other 
possibly modified amino acids other than arginine have never been generated. Making the generation 
of specific antibodies by traditional methods difficult is the need for large amounts of antigen for 
immunization, for which the enzymatic reaction might be limiting, although recently a method was 
published to synthetically generate mono-ADP-ribose-conjugated peptides (Moyle and Muir, 2010). 
Finally, generated ADP-ribose carrying peptides are highly susceptible to phosphodiesterases (PDE) 
that would cleave the ADP ribose and leave only a phospho-ribosylated protein (Figure 10).  
 
 
Figure 10 Cleavage of arginine-ADP-ribose. Depicted are the different sites where ADP-ribose on arginine might be 
cleaved with different mechanisms leading to this cleavage indicated. ARH: ADP-ribosylhydrolase; PDE: phosphodiesterase. 
Modified from (Laing et al., 2011). 
 
Non-enzymatic cleavage gives rise to ornithinylated-proteins in the case of arginine-ADP-ribosylation 
(Stevens et al., 2009), which would be unsuited as antigen for mono-ADP-ribose antibodies as well 
(Figure 10). No published attempts have been made so far at generating antibodies against mono-
ADP-ribose on other amino acids. 
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In addition to detection by specific antibodies, mass spectrometry is a method commonly used to map 
smaller modifications such as phosphorylation and acetylation sites in proteins. HPLC analysis of 
domain D of ARTD1, mono-ADP-ribosylated by the mono-ADP-ribosylating ARTD1 mutant E988Q, 
shows that there are only peptides with one ADP-ribose moiety attached as there is only one extra 
elution peak (Tao et al., 2009). After a trypsin digest of this peak and LC-MS/MS the authors note that 
the modification is lost to a large extent, but are still able to measure two distinct peptides carrying one 
ADP-ribose moiety, E488 and E491. Additionally, they identified a third peptide without measurable 
ADP-ribose, which contains D387 as putative modification site. Upon modification of these residues, 
automodification becomes weaker but is not completely abolished, indicating that there might still be 
other automodification sites. The authors argue that “secondary” modification sites become available 
when the “primary” sites are unavailable (Tao et al., 2009). Contradicting these findings, others 
mutated all glutamic acid residues in this domain and found that this does not influence modification, 
leading to the conclusion that glutamates are not the main acceptor sites (Altmeyer et al., 2009). 
However, aspartic acid residues were not tested. Automodified ARTD1 was stable in 1 M neutral 
hydroxylamine, excluding acidic residues as acceptor site. Upon mutation of several lysine residues, 
automodification is greatly decreased, leading to the conclusion that not glutamic acids but lysines are 
the acceptor sites (Altmeyer et al., 2009). This does not explain why a weak automodification signal is 
still present. Moreover, this suboptimal modification could be an artifact due to structural changes 
after mutation wherein the modification site is much less accessible.  
 
Other attempts at MALDI analysis of ADP-ribosylated samples revealed that it is not possible to 
search databases in the traditional manner by adding 541 Da for the modification (Margarit et al., 
2006) to identify the modified peptides. As e.g. described for arginine-ADP-ribose (Osago et al., 
2009) and as reviewed in (Hengel and Goodlett, 2012), ADP-ribose can be fragmented during 
different mass spec approaches in different manners as schematically depicted (Figure 11). Unspecific 
cleavage during ionization thus complicates the analysis of spectra of ADP-ribosylated peptides. In a 
recent reanalysis of a phosphoproteome dataset, 88 mono-ADP-ribosylation sites were identified 
(Matic et al., 2012). 8 of those represented ribose-phosphate, indicating that the ADP-ribose moieties 
are indeed unstable. Interestingly, 87 mono-ADP-ribosylation sites where present on arginine and only 
1 modified glutamate was identified (Matic et al., 2012). Most of these sites were mapped in liver 
tissue; none were present in 5 out of 9 tissue types studied. Most abundant amongst the identified 
modified proteins are tubulins and translation initiation factors (Matic et al., 2012). This is a hint that 
also this study does not approach the full extent of intracellular ADP-ribosylation, since there should 
be some ARTD automodification or histone modification signals (Burzio et al., 1979). One possible 
explanation is that the more stable arginine-linked mono-ADP-ribose moiety can be measured, but that 
the labile glutamate-linked ADP-ribose moiety is harder to detect. These findings however raise the 
question again which enzymes are responsible for intracellular ADP-ribosylation of arginine. 
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Figure 11 Representation of fragmentation behavior of ADP-ribose in mass spectrometry. Proposed nomenclature for 
(A) mono-ADP-ribose fragmentation (B) cross-ring fragmentation (C) PAR fragmentation. Modified from (Hengel and 
Goodlett, 2012). 
 
The solution for the difficulties presented by the fragmentation of ADP-ribose in MALDI-based 
approaches, might be to employ different methods such as electron transfer dissociation (ETD), as 
glycated lysines proved more stable in measurements with ETD (Fedorova et al., 2010). Since ADP-
ribosylated arginines can also be measured using ETD (Zee and Garcia, 2010), one would assume that 
enzymatically modified lysines should behave similarly. Indeed, a method has been developed to 
enrich ADP-ribosylated peptides and to measure them using ETD (Rosenthal et al., 2011). ARTD1 
was used to optimize this method, but the PAR-chains were degraded by PDE treatment before 
enrichment of the ADP-ribosylated peptides, indicating that mono-ADP-ribosylated peptides can be 
enriched using this method and measured correspondingly. Thus this method might be applicable for 
substrates of the mono-ARTDs as well. A major drawback however is the currently limited 
availability of machines capable of ETD and the complicated nature of the results due to peptide 
backbone fragmentation. 
 
Considering the scarcity of reports on the measurement of ADP-ribosylation and the contradictory 
results, it is obvious that more reliable methods are necessary to be able to study this modification in-
depth.
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Research aims 
The catalytic mechanism of ARTD10 has been analyzed (Kleine et al., 2008), but not further validated 
so far. This study aims to provide an increased understanding of the mono-ADP-ribosylation reaction 
as performed by ARTD10, by expanding the current knowledge of automodification of ARTD10 onto 
novel substrates.  
 
Since no substrates are known besides ARTD10 itself and core histones, it is necessary to identify 
ARTD10s physiological substrates to be able to understand the role ARTD10 plays in cellular 
processes. The results of an ARTD10 and ARTD8 substrate screen are analyzed and validated. The 
consequences of mono-ADP-ribosylation for target proteins are illustrated by investigating the novel 
ARTD10 substrate GSK3β as an exemplary substrate in vitro as well as in cells. Kinase assays are 
employed to assess the effect of mono-ADP-ribosylation on GSK3β activity. 
 
Reversibility of mono-ADP-ribosylation is investigated by testing different ADP-ribosylhydrolases 
and O-acetyl-ADP-ribose-deacetylases. The identified hydrolase with activity towards ARTD10 and 
its substrates, MDO2, is subsequently utilized to test whether the mono-ADP-ribose induced 
functional consequence on GSK3β activity can be reversed by removal of the ADP-ribose moiety. 
 
To increase our understanding of the interaction between ARTD10 and GSK3β bioinformatical 
models were generated to investigate the most likely ADP-ribosylation sites in GSK3β. 
Phosphorylation of ARTD10 by GSK3β is investigated as well as a putative regulatory feedback 
mechanism. 
 
Finally, since no good tools are available to study mono-ADP-ribosylation in cells or to reliably map 
modification sites, mass spectrometry and peptide array based methods are investigated to enable 
future studies of mono-ADP-ribosylation sites in substrates of the mono-ARTDs. 
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Experimental procedures 
 
Materials and Methods are described according to standard protocols used in the Institute of 
Biochemistry and Molecular Biology, RWTH Aachen University, and modified regarding individual 
differences in experimental procedures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“If you try and take a cat apart to see how it works, 
the first thing you have on your hands is a non-working cat.” 
Douglas Adams 
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Materials 
Oligonucleotides 
Construct name Forward (5’  3’) Reverse (5’  3’) 
GSK3S9A GCCCAGAACCACCGCCTTTGCGGAGAG CTCTCCGCAAAGGCGGTGGTTCTGGG 
GSK3K85R AGAACTGGTCGCCATCAGGAAAGTATT
GCAGGACA 
TGTCCTGCAATACTTTCCTGATGGCGACCA
GTTCT 
GSK3E53A_E12
1A_E279A 
CCAGACAGGCCACAAGCAGTCAGCTAT
ACAGAC 
 
CTTCTACTCCAGTGGTGCGAAGAAAGA
TGAGGTCT 
 
GGGAACTCCAACAAGGGCGCAAATCAG
AGAAATGA 
GTCTGTATAGCTGACTGCTTGTGGCCTGTC
TGG 
 
AGACCTCATCTTTCTTCGCACCACTGGAGT
AGAAG 
 
TCATTTCTCTGATTTGCGCCCTTGTTGGAG
TTCCC 
GSK3E211A_D2
64A_E290A 
CAGCTGGTCCGAGGAGCACCCAATGTT
TCGTAT 
 
CAGGGGATAGTGGTGTGGCTCAGTTGG
TAGAAATAAT 
 
AGAAATGAACCCAAACTACACAGCATT
TAAATTCCCTCAAATTAAGG 
ATACGAAACATTGGGTGCTCCTCGGACCAG
CTG 
 
ATTATTTCTACCAACTGAGCCACACCACTA
TCCCCTG 
 
CCTTAATTTGAGGGAATTTAAATGCTGTGT
AGTTTGGGTTCATTTCT 
pDONR/zeo-
CDK9 
GGGGACAAGTTTGTACAAAAAAGCAGG
CTTCATGGCAAAGCAGTACGACTC 
GGGGACCACTTTGTACAAGAAAGCTGGGTC
TTATCAGAAGACGCGCTCAAAC 
pDONR/zeo-
KCNAB1 
GGGGACAAGTTTGTACAAAAAAGCAGG
CTCCATGCAAGTCTCCATAGCCTG 
GGGGACCACTTTGTACAAGAAAGCTGGGTC
TTATGATCTATAGTCCTTCTTGCTGTA 
 
Plasmids 
GSK3β plasmids: 
Name Reference 
pDONR/zeo-GSK3β (Feijs, 2009) 
pcDNA3.1-HA-GSK3β Addgene plasmid 14753 (He et al., 1995) 
pBAC-GST-GSK3β Created by GW-lr-recombination between pDONR/zeo-GSK3β and 
GW-pBAC-GST (K. Feijs) 
pcDNA3.1-HA-GSK3β mutants Created by site-directed mutagenesis with appropriate primers on 
pcDNA3.1-HA-GSK3β (K. Feijs) 
 
ARH1 plasmids: 
Name Reference 
pcDNA4.1-V5-His-mARH1 Gift from J. Moss 
pcDNA4.1-V5-His-mARH1D60, 61A Gift from J. Moss 
pGEX-2T-hARH1 Gift from J. Moss 
pGEX-2T-hARH1D60, 61A  Gift from J. Moss 
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ARTD10 plasmids: 
Name Reference 
pEVRF0-HA-ARTD10 (Yu et al., 2005) 
pEVRF0-HA-ARTD10-G888W (Yu et al., 2005) 
pEVRF0-HA-ARTD10-dNES (Yu et al., 2005) 
pEVRF0-HA-ARTD10-dUIM (Milke, 2007) 
pEVRF0-HA-ARTD10-dK (Chauvistré, 2008) 
pEVRF0-HA-ARTD10-G888W-dUIM (Verheugd et al., manuscript in revision) 
dsRed-ARTD10 (Schuchlautz, 2008) 
dsRed-ARTD10-G888W (Schuchlautz, 2008) 
pEGFP-ARTD10 (Kleine et al., 2012) 
GST-ARTD10(1-255) (Montzka, 2006) 
GST-ARTD10(206-459) (Montzka, 2006) 
GST-ARTD10(408-649) (Montzka, 2006) 
GST-ARTD10(600-868) (Montzka, 2006) 
GST-ARTD10(818-1025) (Montzka, 2006) 
pSUPER_ARTD10_1 (Schuchlautz, 2008) 
pSUPER_ARTD10_6 (Schuchlautz, 2008) 
 
MDO2 plasmids: 
Name Reference 
pcDNA3-HA-MDO2fl/wt (Rosenthal, Feijs et al) 
pcDNA3-HA-MDO2fl/G100E (Rosenthal, Feijs et al) 
pcDNA3-HA-MDO2sh/wt (Rosenthal, Feijs et al) 
pcDNA3-HA-MDO2sh/G100E (Rosenthal, Feijs et al) 
pcDNA3-HA-MDO2sh/4mut (Rosenthal, Feijs et al) 
pETM-33-His-GST-MDO2fl/wt (Rosenthal, Feijs et al) 
pETM-33-His-GST-MDO2fl/G100E (Rosenthal, Feijs et al) 
pETM-33-His-GST-MDO2sh/wt (Rosenthal, Feijs et al) 
pETM-33-His-GST-MDO2sh/G100E (Rosenthal, Feijs et al) 
pETM-33-His-GST-MDO2sh/4mut (Rosenthal, Feijs et al) 
 
Other plasmids: 
Name Reference 
pEVRF0-HA (Matthias et al., 1989) 
pEGFP-C1 Clontech, #6084-1 
pEQ176P2 Derived from pEQ176, where most of the β-galactosidase was cut out by a 
PvuII restriction digest. (J. Lüscher-Firzlaff) 
pEQ176 (Firzlaff et al., 1991) 
pCMV-His6-Ubiquitin Vector encoding for His6-tagged-ubiquitin under control of a CMV-promotor. 
(M. Treier) 
pSUPER_ash_#5_falsh Scrambled oligo ligated into the BglII and HindIII sites of pSUPER. (J. 
Lüscher-Firzlaff) 
pCMV-HA-HectH9 (Adhikary et al., 2005) 
pBabe-Puro (Morgenstern and Land, 1990) 
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pcDNA3-Flag-MYC Human c-MYC was cloned into pcDNA3-Flag by BamHI/BglII restriction 
digests (S. Schreek). 
pM4-mintkluc 4 MYC binding sites cloned in front of the minimal TK promotor in front of 
the luciferase cDNA. 
pDONR/zeo-CDK9 Entry vector created by bp-recombination of a CDK9 PCR fragment and 
pDONR/zeo. (K. Feijs) 
pDONR/zeo-CDK9-D167N Entry vector created by bp-recombination of a CDK9D167N PCR fragment 
and pDONR/zeo. (K. Feijs) 
pDONR/zeo-AFF4 Entry vector created by bp-recombination of a AFF4 PCR fragment and 
pDONR/zeo. (K. Feijs) 
pDONR/zeo-KCNAB1 Entry vector created by bp-recombination of a KCNAB1 PCR fragment and 
pDONR/zeo. (K. Feijs) 
GW-pHA-KCNAB1 Destination vector created by lr-recombination of pDONR/zeo-KCNAB1 and 
GW-pHA (K.Feijs) 
pDONR/zeo Invitrogen, #1253-035 
GW-pHA pEVRF0-HA, made compatible with the GW-system by insertion of the 
Gateway cassette reading frame into the SmaI site. (R. Lilischkis) 
GW-pBAC-GST GW-compatible baculoviral expression vector for GST-tagged proteins (R. 
Lilischkis) 
 
 
Antibodies 
Antigen Clone/information 
α-actin C4, mouse monoclonal, #69100 MP Biomedicals 
α-ARTD10 5H11, rat monoclonal, E. Kremmer, raised against GST-
ARTD10(1-907) 
α-GFP mouse monoclonal, 600-301-215 Rockland 
α-GSK3β H-76 rabbit polyclonal, sc-9166 Santa Cruz 
α-GSK3β-pS9 rabbit monoclonal, Cell Signaling 
α-GST 6G9, rat monoclonal, E. Kremmer 
α-HA 3F10, rat monoclonal, Roche 
α-His H15, rabbit monoclonal, sc-803 Santa Cruz 
α-MCM2 N-19, goat monoclonal, sc-9839 Santa Cruz 
α-MYC N-262, rabbit monoclonal, sc-764 Santa Cruz 
α-p65 E948, rabbit monoclonal, #3987, Cell Signaling 
α-p65-pS468 rabbit monoclonal, #3039, Cell Signaling 
α-γ-tubulin GTU88, mouse monoclonal, #T-6557 Sigma 
α-goat IgG + IgM, HRP-conjugated Jackson Immuno Research 
α-mouse IgG + IgM, HRP-conjugated Jackson Immuno Research 
α-rabbit IgG + IgM, HRP-conjugated Jackson Immuno Research 
α-rat IgG + IgM, HRP-conjugated Jackson Immuno Research 
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Cloning 
DNA preparation 
Small amounts of DNA were purified from bacterial cultures grown overnight at 37ºC using the 
Zyppy™ Miniprep Kit (Zymo Reseach) or using a PureLink™ Quick Plasmid Miniprep Kit 
(Invitrogen) according to manufacturer’s instructions. DNA prepared for subsequent sequencing was 
eluted with ddH2O instead of the elution buffer delivered with the kits. Larger quantities were purified 
using the Qiagen MaxiPrep Kit according to manufacturer’s instructions. Quantity and quality of the 
prepared DNA was measured on a NanoDrop (PeqLab). 
 
Conventional cloning 
Optimal conditions for double digests were determined by using the online DoubleDigest™ tool from 
Fermentas, reactions were carried out at 37ºC for one hour unless recommended differently by the 
DoubleDigest™ program. Digested vectors and inserts were purified from 0.8 – 1.5% agarose gels 
using the Zyppy™ Gel DNA Recovery Kit (Zymo Research) according to manufacturer’s manual. 
When necessary, 5’-phosphates were removed by incubation with thermosensitive alkaline 
phosphatase FastAP™ (Fermentas). Ligation was performed with T4 Ligase (Fermentas) at RT 
overnight, ligated products were transformed into bacteria by heat shock transformation. 
 
Gateway cloning 
Primers to create PCR products with flanking attB sites suitable for the Gateway® System 
(Invitrogen) were designed according to manufacturer’s instructions and ordered from MWG or 
Sigma. 1-2 U Phusion® Polymerase (New England Biolabs) were used in the PCR according to 
manufacturer’s instructions. PCR products were purified from agarose gels using the Zyppy™ Gel 
DNA Recovery Kit (Zymo Research) and used in the bp-recombination reaction overnight according 
to manufacturer’s instructions, with half the reaction volume recommended. Entry vectors created thus 
were sequenced (SeqLab, Göttingen) before continuing with the lr-recombination reactions. 
 
Site-directed mutagenesis 
Primers were designed using Agilent Technologies’ QuickChange Primer Design tool. Phusion® 
Polymerase was used for the PCR according to manufacturer’s instructions with exception of the 
elongation time, which was increased to 1 minute per kb. 2 U Dpn1 (Fermentas) were added to the 
PCR reaction mixture afterwards and incubated for at least one hour at 37ºC to digest all methylated, 
i.e. non-mutated DNA, before heat shock transformation. All constructs created thus were sequenced 
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to ensure successful mutagenesis without acquisition of any other mutations. For multiple mutations in 
one plasmid, sequential rounds of mutagenesis and sequencing were performed. 
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Human, bacterial and insect cell cultivation 
Human cells 
U2OS (ATCC HTB-96™), HeLa (ATCC CCL-2™) and HEK293 (ATCC CRL-1573™) cells were 
kept at a humidified atmosphere at 37ºC with 5% CO2 at all times and were cultivated in DMEM 
(Gibco) supplemented with 10% heat-inactivated fetal calf serum (Gibco) and 1% 
penicillin/streptomycin (Gibco, 10,000 U/ml/10,000 μg/ml). Cells were passaged on Ø10cm dishes 
(Sarstedt) by using 1 ml trypsin (Gibco) to detach the PBS-washed cells from the dish. Passages were 
counted, cells reaching passage 25 were discarded to be replaced by a freshly thawed aliquot.  
 
Stably transfected Flp-In™-T-REx™-293 (Invitrogen R780-07) cell lines, such as the C-TAP-
ARTD10-Flp-In™-T-REx™-293 cells (Schuchlautz, 2005), were cultured in DMEM supplemented 
with 15 μg/ml blasticidin S (InvivoGen) and 50 μg/ml hygromycin B (InvivoGen).  
 
Cryoconservation 
To thaw cells, frozen cells were warmed in a water bath at 37ºC and transferred to a 15 ml tube 
immediately after melting of the ice crystals. 9 ml pre-warmed DMEM was added. After pelleting of 
the cells by centrifugation, medium was removed, followed by resuspension of the pellet in 10ml fresh 
fully supplemented DMEM and cells were plated out on a Ø10 cm dish. 
 
To freeze cells, 80% confluent cells were removed from the dishes by trypsinization. The cells were 
pelleted and washed with PBS, followed by a resuspension in a solution of 10% DMSO and 90% FCS. 
Cells were transferred to a cryotube (Nunc) and kept on ice for 20 minutes, after which the tubes were 
transferred to -80ºC in an insulated box for slow cooling for 24-72 hours. For long-term storage, cells 
were transferred to -150ºC. 
 
Bacterial cells 
Several different bacterial strains were used, E.coli XL10 Gold® were generally used for plasmid 
preparation and conventional cloning, E.coli DH5α™ were employed for GateWay® cloning, E.coli 
BL21 were used for regular protein purification and E.coli Rosetta-Gami were used for proteins 
rendering multiple breakdown products when purified from E.coli BL21. 
 
XL10-Gold® 
(Stragene)  
Tetr D(mcrA)183 D(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 
relA1 lac Hte [F’ proAB lacIqZDM15 Tn10 (Tetr) Amy Camr]  
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DH5α™ (Invitrogen) F- 80dlacZ M15 (lacZYA-argF) U169 recA1 endA1 hsdR17(rk- mk+) phoA supE44 
- thi-1 gyrA96 relA1  
BL21(DE3)pLysS 
(Stratagene) 
B F- dcm ompT hsdS(rB– mB–) gal (DE3) [pLysS Camr]  
Rosetta-Gami™ 
B(DE3)Lys 
(Novagen) 
F–ompT hsdSB (rB– mB–) gal dcm lacY1 ahpC (DE3) gor522::Tn10 trxB 
pLysSRARE (Cam
R
, Kan
R
, Tet
R
) 
 
Bacterial transformation was achieved by first thawing the bacteria on ice, followed by mixing with 
5 ng-1 μg DNA in 14 ml round-bottom tubes (Falcon). After an incubation of 10 minutes, bacteria 
were heat-shocked for 45 seconds at 42ºC immediately followed by a one-minute incubation on ice. 
Pre-warmed LB medium (1% tryptone, 0.5% yeast extract, 1% NaCl, pH 7.0) was added and the 
bacteria were allowed to recover at 37ºC for 30-60 minutes. Finally, bacteria were pelleted by 
centrifugation and plated out on LB-plates. LB-Amp plates contained 100 μg/ml ampicillin (Binotal), 
LB-kan plates contained 30 μg/ml kanamycin (Applichem) and low-salt-LB plates contained 50 μg/ml 
zeocin (Invivogen). Low salt LB medium contained only 0.5% NaCl. 
 
Insect cells 
SF9 cells (ATCC CRL-1711™) were kept in Grace’s medium (Gibco) supplemented with 10% FCS 
(Gibco) and 20 μg/ml gentamycin (Merck) at 27ºC.  
For virus production, 1x10
6
 cells were seeded in 10 ml complete medium and allowed to settle on the 
bottom of the flask. 200 μl complete medium were mixed with 10 μl LT1 (Mirus) and 2 μg pBAC-
GST-GSK3β was mixed with 0.1 μg BaculoGold DNA (BD Biosciences). Both mixtures were 
incubated for 10 minutes, mixed together and incubated another 5 minutes. The medium was replaced 
by FCS-free medium and the transfection mixture was added drop-wise to the cells. Cells were 
incubated for 4 hours, washed once in FCS-free medium and finally 5 ml medium was added. After 7 
to 10 days, the supernatant was filtered through a 0.22 μM filter and added to newly seeded cells. 
Protein expression was tested in the left over cells after the first amplification round. For final protein 
purification, 2x10
7
 cells were seeded in 30 ml medium per 175 cm
2
 flask (Greiner). One ml virus-
containing sterile-filtered supernatant was added to each flask, with one ml containing approximately 
1x10
8
 plaque forming units. 
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Protein purification and detection 
Human tandem affinity protein purification 
Stable C-TAP-ARTD10-Flp-In™-T-REx™-293 cells were grown under selection until a minimum 
amount of 6 Ø10 cm plates with a confluency of 80% were available, upon which the cells were 
transferred to spinner flasks in regular DMEM. Protein expression was induced by adding 1 µg/ml 
doxycycline for 16 hours. Cells were pelleted by centrifugation at 500 xg, washed with ice-cold PBS 
and lysed using 15 ml TAP lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 10% 
Glycerol, 1% NP-40, 1 mM DTT, 100 µM NaVO4, 0.14 mg/ml aprotinin, 4 µM leupeptin, 0.5 mM 
PMSF) per 500 ml suspension and incubated 30 minutes under rotation, followed by centrifugation at 
10,000 xg for 20-30 minutes. Samples were kept on ice throughout the entire following procedure. 
The supernatant was transferred to 200 µl equilibrated IgG Sepharose beads (Amersham Biosciences) 
and incubated for 1 hour under rotation. Beads were pelleted at 200 xg in 2 minutes and washed 1x in 
lysis buffer, 2 times in TEV buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 1 mM DTT) 
and subsequently resuspended in 200 µl TEV buffer. 2 µl TEV protease (Invitrogen) was added and 
samples were incubated for 2 hours under vigorous shaking or alternatively incubated overnight. After 
centrifugation at 200 xg, the supernatant was transferred to 200 µl equilibrated CaM beads 
(Amersham Biosciences) in 1.5 ml CaM binding buffer (10 mM Tris pH 7.5, 150 mM NaCl, 0.2% 
NP-40, 1 mM MgOAc, 2 mM CaCl2, 1 mM Imidazol, 10 mM β-mercaptoethanol). CaCl2 was added in 
a 1:200 ratio and the samples were incubated for 90 minutes under rotation. Beads were washed 3 
times in CaM wash buffer (50 mM NH4HCO3, 75 mM NaCl, 1 mM MgOAc, 1 mM Imidazol, 2 mM 
CaCl2) and resuspended in two volumes elution buffer. After an incubation period of 30 minutes, 
beads were spun down and supernatants collected. Samples were stored at -80ºC, with addition of 
MgCl2 in a ratio of MgCl2:eluate 1:200. Concentrations were determined using SDS-PAGE and a BSA 
standard, enzymatic activity was tested in ADP-ribosylation assays. Tested protein was stored in 
aliquots to avoid repeated freezing and thawing. 
 
E.coli GST-protein purification 
The construct of interest was transformed by heat-shock transformation as described above. A single 
colony was picked to inoculate a starter culture in 49 mL LB medium, supplemented with 0.5% 
glucose and the appropriate antibiotic. This culture was allowed to grow overnight at 37ºC. 25 mL of 
the starter culture was transferred to 500 ml LB also supplemented with glucose and antibiotic. At an 
OD600 in the range of 0.5-0.7, protein expression was induced by addition of 0.5 mM IPTG and 
incubated for another 2 to 3 hours at 37ºC, followed by an overnight incubation at RT. Bacteria were 
pelleted by centrifugation at 5,000 xg and either frozen at -80ºC to continue the next day or 
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immediately resuspended in 30 ml ice-cold TNE (20 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA 
pH 8.0, 5 mM DTT, 1 mM Pefa-Bloc, 1% Trasylol). After lysis on ice for 30 minutes with 100 µg/ml 
lysozyme, cells were solubilized by sonication. The samples were centrifuged at 10,000 xg and 4ºC, 
followed by a 1-2 hour incubation of the supernatant with 0.5 ml Glutathion Sepharose 4B Beads 
(Amersham Biosciences). Beads were subsequently washed with PBS three times and transferred to a 
0.8x4 cm chromatography column (Biorad). After washing with GST wash buffer (100 mM Tris pH 
8.0, 120 mM NaCl), bound proteins were eluted in 3 fractions of 300 µl GST-elution buffer (20 mM 
glutathione in GST wash buffer). Samples of each fraction were subjected to SDS-PAGE and 
coomassie staining and quantified using a BSA standard. 
 
E.coli His-protein purification 
E.coli His-protein purifications were performed similar to the E.coli GST-protein purifications, with 
the following differences. Pellets were resuspended in IMAC lysis/wash buffer (20 mM HEPES pH 
7.5, 10% glycerol, 300 mM NaCl, 0.1% NP-40, 5 mM imidazole and 14 μg/ml aprotinin) instead of 
TNE buffer. Instead of Glutathion Sepharose 4B Beads, 0.5 ml TALON™ Metal Affinity Resin (BD 
Biosciences) was used per 500 ml bacterial culture. Beads were washed in IMAC lysis/wash buffer, 
the protein was eluted by incubation of the beads in IMAC elutionbuffer (20 mM HEPES pH 7.5, 10% 
glycerol, 200 mM NaCl, 0.1% NP-40, 10 mM EDTA, 10 mM DTT and 14 μg/ml aprotinin) for 10 
minutes, which was repeated, resulting in two elution fractions per purification. 
 
Insect GST-protein purification 
SF9 cells were infected as described above. 5-7 days after infection cells were pelleted by 
centrifugation at 500 xg, medium removed and the pellet resuspended in kinase lysis buffer (50 mM 
HEPES pH 7.5, 0.5% Tween-20, 10% glycerol, 300 mM NaCl, 5 mM NaF, 1 mM EDTA, 1 mM 
EGTA, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 0.1 mM orthovanadate, 1 mM pefabloc and 1 mM 
DTT). The lysate was sonicated with 2 x 15 pulses at 70% output. Debris was pelleted by 10 minutes 
centrifugation at 15,000 xg and the supernatant was incubated with equilibrated Glutathion Sepharose 
4B Beads (Amersham Biosciences). Beads were washed with wash buffer I (50 mM HEPES pH 7.5, 
0.5% Tween-20, 10% glycerol, 300 mM NaCl, 5 mM NaF, 1 mM EDTA, 1 mM EGTA, 0.1 mM 
orthovanadate, 1 mM pefabloc and 1 mM DTT), transferred to eppendorf tubes in wash buffer II 
(50 mM HEPES pH 8.0, 0.01% Tween-20, 10% glycerol, 100 mM NaCl, 1 mM pefabloc and 1 mM 
DTT). Protein was eluted in 500 μl elution buffer (20 mM glutathione in wash buffer II) by overnight 
incubation at 4ºC. 
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SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide running gels were prepared with acrylamide concentrations 
ranging from 10% to 20%, depending on the size of the proteins analyzed. Stacking gels contained 5% 
acrylamide. Samples were boiled briefly in sample buffer (2x: 160 mM Tris pH 6.8, 20% glycerol, 
10% SDS, 0.25% bromophenol blue, 100 mM β-mercapthoethanol) before loading. Gels were placed 
in a tank with Laemmli buffer (25 mM Tris base, 250 mM glycine, 0.1% SDS) and 25 mA was 
applied until the samples formed one line in the stacking gel, after which the current was increased to 
35 mA. A Protein Ladder (PageRuler™ Prestained Protein Ladder, Fermentas) was loaded onto each 
gel to be able to estimate protein sizes. 
 
Rapid coomassie staining 
Coomassie stains proteins nonspecifically through interaction with hydrophobic and cationic amino 
acids. After SDS-PAGE, gels were fixed and stained in staining solution (10% acetic acid, 0.006% 
coomassie brilliant blue G250 (Bio-Rad)) under slight agitation until bands became visible. Gels were 
destained overnight in ddH2O to reduce background staining. 
 
Western Blot 
Using a semi-dry blotting system, the proteins were transferred from the gel onto a nitrocellulose 
membrane (Millipore) in semi-dry blotting buffer (25 mM Tris-base, 192 mM glycine, 20% 
methanol), applying 2 V per cm
2
 for one hour. The membrane was dyed with Ponceau (0.2% Ponceau 
S in 3% TCA) to visualize the proteins and check transfer efficiency. Subsequently the membranes 
were blocked in 5% non-fat milk in PBS-T (140 mM NaCl, 2.6 mM KCl, 2 mM Na2HPO4, 1.45 mM 
KH2PO4, 0.05% Tween-20) or 5% non-fat milk in TBS-T (50 mM Tris-HCl, 140 mM NaCl, 0.05% 
Tween-20) for phospho-specific antibodies. The first antibody was applied either overnight at 4ºC or 
for 2 hours at RT, diluted in a range of 1:200 to 1:2000 in PBS-T or in 5% BSA in TBS-T for 
phospho-specific antibodies. 0.02% sodium azide was added for storage of diluted antibodies at 4 ºC. 
After several PBS-T or TBS-T washes, the secondary, species-specific horseradish peroxidase (HRP)-
coupled antibody was applied for 30-60 minutes at RT in 5% non-fat milk in PBS-T or in 5% non-fat 
milk in TBS-T for phospho-specific antibodies. After further PBS-T or TBS-T washes, the substrate 
for HRP, ECL Pico or Femto (Pierce), was applied and the resulting chemiluminescence signals read-
out immediately using a LAS-3000 (Fuji). 
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Cell-based assays 
Transfection methods 
Calcium-phosphate precipitation-based transfection 
Transfections of U2OS, HeLa and HEK293 cells were performed using the calcium phosphate 
precipitation technique unless stated otherwise. U2OS were seeded at a density of 8 x10
5
 cells per 
Ø10 cm dish the day before transfection, HeLa cells at a density of 8.5 x10
5
 cells per Ø10 cm dish. 
HEK293 cells were seeded two days before transfection at a density of 1x10
6
 cells per Ø10 cm dish. 
20 μg DNA was diluted in 950 μl HBS buffer (138 mM NaCl, 17 mM Hepes, 5 mM KCl and 
0.71 mM Na2HPO4  μl 2.5 M CaCl2 was added and the mixture was mixed 
thoroughly. After an incubation of 20 to 40 minutes, the mixture was added drop-wise to the medium. 
Cells were washed with warm PBS 12-24 hours after transfection and were collected for subsequent 
assays 24-48 hours after transfection. 
 
Lipid-based transfection 
Dharmacon siRNA pools were transfected using Lipofectamin™ (Invitrogen) according to 
manufacturer’s instructions. U2OS cells were seeded in Ø6 cm dishes at a higher density than 
recommended, approximately 80% confluent and were divided equally onto 2 Ø6 cm dishes the day 
after transfection. 
 
Protein preparation 
Cells were washed with cold PBS, subsequently 300-350 μl TAP (see above) or RIPA lysis buffer 
(10 mM TrisCl, pH 7.4, 0.15 M NaCl, 1% NP-40, 0.1% SDS, 1% deoxycholate) was added to the 
plates. ProteoBlock™ Protease Inhibitor Cocktail (Fermentas) was added freshly. Additional 
phosphatase inhibitors (0.1 mM vanadate, 20 mM β-glycerophosphate and 50 mM ocadaic acid) were 
added freshly only when preparing lysates for phospho-analysis. Cells were collected by scraping and 
transferred to eppendorf tubes. RIPA lysates were sonicated in a water-bath sonicator (Bioraptor, 
Diagenode) for 15 minutes with 30 second cycles at maximum intensity and were subsequently 
cleared by centrifugation. TAP lysates were cleared directly by centrifugation at 16,000 xg for 15-20 
minutes at 4ºC. The supernatants were transferred to a new tube and stored at -20 ºC or analyzed 
directly with SDS-PAGE. 
 
Colony Formation Assays 
HeLa or U2OS cells were seeded in Ø6 cm dishes at a density of 3.0 x10
5
 respectively 2.5 x10
5 
cells 
per dish, as determined using a Casy®Counter (Innovatis). One day after seeding, cells were 
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transfected with indicated amounts of genes of interest and 0.8 μg pBabePuro on a total of 8 μg for 
selection, rendering transfected cells puromycin resistant. 6-16 hours after transfection the culture 
medium was refreshed and puromycin (Sigma) was applied with a final concentration of 2 µg/ml. 
Selection took place for 24 hours, after which the medium was refreshed again. Colonies were allowed 
to grow for 4-10 days, with refreshment of the medium as necessary. Cells were washed with PBS 
once time and stained with 0.2% methylene blue in methanol. After an incubation of approximately 30 
minutes the dye was removed, the plates were washed with ddH2O, air-dried and documented. 
 
Reporter gene assays 
Cells were seeded at a density of 4-5 x10
4
 cells per well in a 12-well plate and transfected the next day 
using the calcium-phosphate method. A total amount of 2 μg DNA was transfected per well, with 
0.2 μg β-galactosidase control plasmid, 0.2 μg pEGFP, 0.5 μg reporter-gene construct, 0.2 μg 
transcription factor of interest, e.g. MYC, and varying amounts of other constructs of interest. Cells 
were washed 24 hours after transfection and lysed 48 hours after transfection in extraction buffer 
(5 mM Tris pH 7.8, 0.4 mM EDTA, 2% glycerol, 0.2% Triton-X100 and 10 mM DTT). Cell debris 
was removed by 20 minutes centrifugation at 4ºC and 16,000 xg. 20 μl cleared lysate was pipetted into 
one white and one clear 96-well plate. 100 μl β-galactosidase buffer (60 mM Na2HPO4, 40 mM 
NaH2PO4.H2O, 10 mM KCl, 1 mM MgSO4 and 20 mM β-mercaptoethanol) was added to the lysates in 
the clear plates, 100 μl luciferase buffer (25 mM glycylglycin, 15 mM MgSO4 2O and 5 mM 
ATP) was added to the lysates in the white plates. 25 μl ortho-nitrophenyl-β-galactoside (ONPG) 
(Applichem) was added in regular time intervals to the lysate-β-galactosidase buffer mixture in the 
clear plates. The reaction product, o-nitrophenol (ONP), has a visible yellow color and can be 
measured. The enzymatic reaction was stopped by adding 60 μl Na2CO3 in the same time intervals and 
subsequently measured at 405 nm using a spectrometer (Victor, PerkinElmer). After automated 
addition of 35 μl luciferin (0.25 mM in 25 mM NaOH) (Applichem) luciferase activity was measured 
at 405 nm. Relative luciferase units (RLU) were calculated by dividing the measured luciferase values 
through the β-galactosidase extinction values. 
 
In vivo ubiquitination 
Cells were seeded and transfected with the calcium-precipitate methods as described above. 8 μg 
pCMV-His6-Ubiquitin, 2 μg pEGFP and 4-10 μg of constructs of interest were transfected. 
Optionally, cells were treated with the proteasome inhibitor MG132 (Sigma) at a final concentration of 
25 μM for 2-4 hours. Cells were lysed in 8 M urea buffer (8 M Urea, 0.1 M NaPO4, 10 mM imidazole) 
and sonicated. Lysates were cleared from cell debris by full-speed centrifugation at RT. Supernatants 
were incubated with 20 μl equilibrated TALON™ Metal Affinity Resin (BD Biosciences) for 2-3 
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hours at RT. After extensive washing in urea buffer, beads were boiled in sample buffer supplemented 
with 200 mM imidazole. Samples were analyzed by SDS-PAGE and Western Blot. 
 
(co-)Immunoprecipitation 
Cells were lysed in 350 µl co-IP buffer (20 mM HEPES pH 7.4, 50 mM NaCl, 30 mM Na4P2O7, 
50 mM NaF, 0.2% TritonX-100, 10% glycerol, 5 µM ZnCl2), freshly supplemented with 
ProteoBlock™ Protease Inhibitor Cocktail (Fermentas), 100 µM NaVO4 and 10 mM natrium-β-
glycerophosphate or in 350 μl TAP-lysis buffer (see above) per 10 cm plate or per 7 x 105 suspension 
cells and kept on ice for 10-30 minutes. Lysates were cleared from cellular debris by high-speed 
centrifugation for 20 minutes. Supernatants were incubated two hours or overnight at 4 ºC with an 
antibody recognizing the protein of interest and beads (protein G or A-Sepharose 4 Fast Flow, GE 
Healthcare) appropriate for the antibodies. Beads were washed in co-IP buffer or TAP-lysis buffer 
before boiling in sample buffer and loading on SDS-PAGE.  
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In vitro assays 
ADP-ribosylation assays 
ADP-ribosylation assays were carried out at 30ºC for 30 minutes unless indicated otherwise. The 
reaction mixture (50 mM Tris-HCl, pH 8.0, 0.2 mM DTT, 5 mM MgCl2, 50 μM β-NAD
+
 (Sigma) and 
1 μCi [32P]-β-NAD+ (Perkin Elmer)) was added to 1 μg purified substrate protein or to IgG-beads with 
immunoprecipitated material and 0.5 μg enzyme in a total reaction volume of 30 μl. Reactions were 
stopped by adding SDS sample buffer, boiled and run on SDS-PAGs. Incorporated radioactivity was 
analyzed by exposure of the dried gel to X-ray film (Fujifilm, 100NIF). Samples used in subsequent 
kinase assays were incubated with 50 μM β-NAD+ only and cooled on ice before washing of the beads 
with kinase assay buffer. 
 
Kinase assays 
Kinase buffer: 5 mM MOPS pH 7.2, 2.5 mM β-glycerophosphate, 1 mM EGTA, 0.4 mM EDTA, 
4 mM MgCl2, 50 μM DTT and 40 ng/μl BSA. [
32
P]-γ-ATP (Hartmann) was diluted to 0.16 μCi/μl in 
250 μM ATP in 3x kinase assay buffer. 25 ng GST-GSK3β or precipitated material was incubated in a 
reaction volume of 25 μl containing 5 μl 0.16 μCi/μl [32P]-ATP-solution and 5 μg substrate peptide 
RRRPASVPPSPSLSRHS(pS)HQRR (Millipore), unless titrated in indicated concentrations. After 
incubating at 30ºC for 15 minutes the reaction was stopped by placing on ice. Routinely 10 μl aliquots 
were spotted on P81 paper in duplicate, washed with 0.5% phosphoric acid and air-dried before 
scintillation counting. SDS-sample buffer was added to the samples analyzed by SDS-PAGE and 
autoradiography. Statistical significance was determined by employing two-sided Student’s t-tests. 
 
de-ADP-ribosylation assays 
ADP-ribosylation assays were performed as described above with 1 μCi [32P]-β-NAD+, but were 
terminated by washing the beads with coupled proteins in high-salt ADP-ribosylation assay buffer 
(50 mM Tris-HCl, pH 8.0, 0.2 mM DTT, 5 mM MgCl2, 200 mM NaCl). Subsequently, 500 ng MDO2, 
ARH1 or Macro1-3 were added to the beads in 30 μl high-salt ADP-ribosylation assay buffer. After 
incubation at 30ºC for 20-30 minutes, the reaction was stopped by addition of SDS sample buffer and 
boiling for analysis by SDS-PAGE and autoradiography. For subsequent kinase assays, beads with 
coupled GST-GSK3β were cooled and washed after incubation with MDO2 to allow kinase assays as 
described above. Statistical significance was determined by employing two-sided Student’s t-tests. 
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GST-pull down assays 
GST-pull down assays were used to examine direct interactions between proteins. Two different 
methods were used, one utilizing in vitro translated protein and one using purified proteins only. For 
in vitro translation, ARTD10 or MYC were in vitro translated exactly as recommended by the 
manufacturer of the kit (Promega), using [
35
S]-methionine, T3 polymerase and a pBlueScript ARTD10 
or MYC plasmid. Glutathion Sepharose 4B Beads were equilibrated using GST pull-down buffer 
(20 mM HEPES pH 7.4, 50 mM NaCl, 1.5 mM EDTA, 0.1% NP40, 0.1% aprotinin, 1 mg/ml 
pefablock, 1 g/ml pepstatin A, 0.5 μg/ml leupeptin) and subsequently incubated for at least 90 minutes 
at 4ºC with the GST-tagged protein of interest. After several washes with GST-pull-down buffer, in 
vitro translated protein was added to the beads and incubated for 2 hours at 4ºC under constant 
rotation. After further washes, the beads were boiled in sample buffer and analyzed using SDS-PAGE. 
10% of the in vitro translated protein was loaded as a control for the in vitro translation. Gels were 
stained with coomassie blue and destained overnight. Amplify (GE Healthcare) was applied for 30 
minutes, followed by vacuum-drying of the gel and exposure to film at -80ºC using an amplifier 
screen. 
For non-labeled pull-downs, a GST-tagged protein was coupled to Glutathion Sepharose 4B Beads as 
described above, upon which a second, differentially tagged protein was added. This mixture was 
incubated at 4ºC under constant rotation for 1-2 hours, washed in GST-pull down buffer and analyzed 
by SDS-PAGE and Western Blot. Both proteins were detected in the Western Blot, in the pull-down 
as well as in input samples. 
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Mass spectrometry methods 
Identification of phosphorylation sites 
For the identification of unknown phosphorylation sites in proteins, in vitro kinase assays were 
performed as described above. All solutions were filtered through a 0.22 μm filter (Millipore) to avoid 
possible contaminations and work was carried out under a clean bench as far as possible. 4x sample 
buffer was added to the kinase assay mixture, boiled for 5 min at 95 ºC and subsequently cooled on 
ice. Freshly prepared iodoacetamid was added to a final concentration of 100 mM and incubated in the 
dark at 55 ºC for 10 minutes. Subsequently, the samples were subjected to SDS-PAGE as described 
above. After electrophoresis, the gel was fixed with sterile-filtered fixing solution (25% isopropanol, 
10% acetic acid) and stained with Gel-Code Blue (Pierce). Gels for analysis by the laboratory of 
David W. Litchfield (University of Ontario, London, Canada) were documented, shrink-wrapped and 
shipped. 
 
Identification of mono-ADP-ribosylation-sites 
In-solution trypsin digests of mono-ADP-ribosylated samples 
ADP-ribosylation assays were performed as described above but without radiolabeled NAD
+
. 30 μl 
8 M urea (in 50 mM ammonium bicarbonate) was added to each assay, which was then incubated for 
15 minutes. 10 mM freshly prepared DTT was added, followed by an incubation of one hour at 56ºC. 
Finally, iodoacetamide was added to a final concentration of 55 mM and the mixture was incubated in 
the dark for 45 minutes at RT. This mixture was diluted with 50 mM ammonium bicarbonate to 2 M 
urea. Trypsin (Trypsin Gold, Promega) was added in a ratio trypsin:protein 1:50. Digestion took place 
overnight at 37ºC and was stopped by freezing at -20ºC. Samples were desalted by using C-18 (3M) 
home-packed tips or purchased C-18 tips (Pierce ThermoScientific). Tips were wetted with 
acetonitrile and washed with 0.1% trifluoroacetic acid (TFA) before loading of the samples. After 
washing again with 0.1% TFA, samples were eluted in 80% acetonitrile containing 0.1% TFA. 
Samples were dried after desalting. 
 
Purification of mono-ADP-ribosylated peptides 
Tryptic peptides from ADP-ribosylation reactions were produced as described above and subsequently 
incubated with equilibrated ProSep® PB Resin (Millipore), essentially as described in (Rosenthal et 
al., 2011). 10% of the tryptic peptides were saved to analyze by MALDI directly. Eluates in 0.1% 
acetic acid were completely dried in a SpeedVac Concentrator (Eppendorf) before redissolving and 
MALDI analysis. Alternatively, 50 μM biotin-labeled NAD+ was used in the ADP-ribosylation 
reaction and the subsequent pull-down performed with Dynabeads® MyOne Streptavidin C1 
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(Invitrogen). These samples were washed in RIPA buffer and ddH2O before elution in 6M guanidine-
HCl. Samples were desalted and dried before MALDI analysis.  
 
Chromatographic separation of mono-ADP-ribosylated peptides 
ADP-ribosylation assays were performed with approximately 2 μg GST-ARTD10(818-1025) and 
10 μCi [32P]-NAD+. After the 30-minute incubation, samples were boiled in sample buffer and loaded 
on 12%-SDS-PAGs. After coomassie staining as described above, gels were vacuum-wrapped and 
exposed to an X-ray film overnight to assess incorporated radioactivity. In-gel tryptic digests were 
performed basically as described before (Kelm et al., 2002). In brief, gel pieces were cut out and 
macerated, subsequently incubated with 40% isopropanol, then with 50% methanol/50 mM 
NH4HCO3. Gel pieces were dried completely in the SpeedVac Concentrator before resuspension in 
50 μl 50 mM NH4HCO3, containing 1.5 μg trypsin (Trypsin Gold, Promega). After overnight 
incubation with shaking at 37 ºC, another 1.5 μg trypsin was added and incubated for 6-16 hours. The 
supernatant was taken off and 100 μl acetonitrile was added to the gel pieces. After 30 minutes 
shaking at 37ºC, supernatants were collected and pooled with the previous supernatants and dried in 
the SpeedVac Concentrator. Peptides were redissolved in 30 μl pH 1.9 buffer (van der Geer and 
Hunter, 1994) and spotted onto cellulose thin layer plates (Merck) with 0.75 μl aliquots at a time. Two 
different buffers were used for chromatography, phospho chromatography buffer and isobutyric acid 
buffer as described by Hunter (van der Geer and Hunter, 1994), with the runs taking 10-12 hours. 
After completion, plates were air-dried, wrapped in plastic wraps, marked fluorescently and exposed 
to films in the presence of intensifier screens at -80ºC. 
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Peptide- and ProtoArrays® 
ProtoArrays® 
All solutions used were filtered through 0.22 μm filter devices prior to use to eliminate background-
causing dust particles. ProtoArrays® (Invitrogen) were removed from -20ºC and allowed to thaw at 
RT for 20 minutes before transferring to a 10 cm tissue culture plate. Roti®-Block (Roth) was used to 
block the arrays by incubating for 1 hour at 4ºC, shaking with 50 rpm. Arrays were washed once in 
plain reaction buffer (50 mM Tris-HCl, pH 8.0) and dried at the back and sides with Kimwipes®. The 
reaction mixture (50 mM Tris-HCl, pH 8.0, 0.2 mM DTT, 4 mM MgCl2, 25 μM biotin-NAD
+
 
(Trevigen) and approximately 1.5 μg enzyme) was applied to the slides upon which LifterSlips™ 
(Nunc) were placed on the arrays to prevent evaporation of the reaction mixture. This was incubated 
for 1 hour at 30ºC and subsequently washed at least 3x with 1% fatty-acid-free BSA in TBS/T, 3x 
with 0.5% SDS in TBS/T and again at least 3x with 1% fatty-acid-free BSA, each wash step taking 10 
minutes. To detect the biotinylated proteins, streptavidin-AlexaFluor® 647 (Invitrogen) was applied in 
the dark for 90 minutes at 4ºC at a concentration of 2 μg/ml in 1% fatty-acid-free BSA in TBS/T, after 
which 5 10-minute wash steps with 1% fatty-acid-free BSA in TBS/T and 5 wash steps with ddH2O 
were performed. Arrays were centrifuged at 200xg for 2 minutes to remove residual ddH2O and 
subsequently analyzed using an Axon GenePix® 4100A microarray reader with the GenePix®Pro 6.0 
program. Results were analyzed with the Prospector software provided by Invitrogen.  
 
Z-scores were calculated to assess statistical significance, according to the following formula: z = (x-
μ)/σ where x is the raw value, μ the population mean and σ the standard deviation of the population. 
All proteins having a Z-score ≥ 2.5 were considered as a positive hit and were displayed in the 
supplementary tables. Gene ontology analysis was performed with the online available 
BioCompendium data analysis platform (http://biocompendium.embl.de/). 
 
PepStar™ Histone Tail Peptide Arrays 
All solutions used were filtered through 0.22 μm filter devices prior to use to eliminate background-
causing dust particles. Arrays (JPT, Berlin) were placed in a cell culture dish with the label facing up. 
This dish was placed in a larger dish stuffed with wet Kimwipes®. Roti®-Block (Roth) was applied to 
block the arrays by incubating 1 hour at RT. Subsequently arrays were washed twice in TBS and once 
in Tris pH 8.0. Spacers were placed on the ends of the arrays, a dummy slide was placed on top, 
leaving a small strip of array uncovered to pipette the reaction mixture onto, as depicted in Figure 12.  
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Figure 12 Schematic overview of PepStar™ Histone Tail Peptide Array setup. From Protocol PepStar™ Histone Tail 
Peptide Array, JPT. The subsequent steps in the preparation of the enzymatic reaction are displayed. 
 
300 μl reaction mixture (25 μM biotin-NAD, 2 μg TAP-ARTD10 or BSA, 50 mM Tris pH8.0, 0.2 mM 
DTT, 4 mM MgCl2) was pipetted between array and dummy slide, upon which the dummy slide could 
be slid into place. The ADP-ribosylation reaction took place for one hour at 30ºC, followed by two 
washes in TBS, one in 0.5 % SDS and two in TBS/T. AlexaFluor® 647 was applied in a 1:5000 
dilution in TBS/T for 90 minutes in the dark. 3 More wash steps with TBS/T followed to remove 
antibody traces, 5 water wash steps were applied to completely clean the arrays. Arrays were air-dried 
and subsequently analyzed using an Axon GenePix® 4100A microarray reader with GenePixPro® 
6.0. The resulting gpr-files were then analyzed by JPT. 
Experimental procedures | Bioinformatical analysis 
 
50 
Bioinformatical analysis 
Docking of NAD into the catalytic center of ARTD10 
The structure of ARTD10 in complex with NAD
+
 was predicted by protein-ligand docking, based on 
the published crystal structure of ARTD10 (Protein Data Bank (PDB) ID 3HKV) in complex with the 
inhibitor 3-aminobenzamide (3AB). In order to guide the docking procedure, we introduced two sets 
of information: 1) interactions (hydrogen bonds and hydrophobic interactions) formed by 3AB at its 
ARTD10 pocket; 2) common structural features shared by other ARTs and ADP-ribosylating toxins 
(Lee et al., 2010). The protein-ligand docking was performed using the software HADDOCK 
(Dominguez et al., 2003). Hydrogen bonds and hydrophobic interactions formed between 3AB and 
ARTD10 were derived from the “Ligand explorer” feature at the PDB website. They were introduced 
as unambiguous distance restraints, i.e. restraints unambiguously derived from experimental data. 
However, in HADDOCK it is also possible to introduce ambiguous interaction restraints (AIRs), 
generally defining interface interactions. AIRs involve two sets of residues, named active and passive 
residues. Active residues are those known to make contacts within the complex and solvent accessible. 
Passive residues are their closest solvent accessible neighbors. In this case, the ARTD10 catalytic 
residues H887 and Y919 and NAD
+
 were defined as active residues. Thus, we docked the 8 NAD
+
 
conformations described in (Lee et al., 2010) against the ARTD10 structure, which underwent a 
preliminary short (2000 steps) energy minimization. The ligand parameters were obtained using the 
PRODRG server (http://davapc1.bioch.dundee.ac.uk/prodrg/). For each docking run, that generated 
1000 rigid and 200 water-refined docking complexes, the best structure was retained. Among the 8 
results, the ARTD10-NAD
+
-complex obtained by using the NAD
+
 conformation from ART2.2 was 
selected, as it showed the lowest scoring function value and satisfied all of the imposed restraints. 
 
Modeling of the interaction between ARTD10 and GSK3β 
The protein-protein docking calculations performed using HADDOCK (Dominguez et al., 2003) 
require the definition of ambiguous distance restraints, usually derived from experimental data, in 
order to guide the docking procedure. In this study, the restraints were defined as follows: 1) In 
ARTD10, the catalytic residues H887, Y919, and I987 were defined as active residues. The ARTD10 
structure used includes the cofactor NAD
+
 docked in the catalytic site as described above. 2) In 
GSK3β, every glutamate (E), aspartate (D), lysine (K) and arginine (R) was alternatively defined as 
active residue. After each docking run, the best structure belonging to the best cluster was retained. 
Results were evaluated on the basis of: a) the HADDOCK scoring function; b) the interacting surface; 
c) the free-energy solvation, d) salt bridges and hydrogen bonds formation. c) and d) were evaluated 
with the PISA method (Krissinel and Henrick, 2007). 
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“The most exciting phrase to hear in science, the one that 
heralds new discoveries, is not ‘Eureka!’ (I found it!) but ‘That’s 
funny…’.” 
Isaac Asimov 
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Identification of novel substrates of ARTD10 and ARTD8 
Previous work has identified ARTD10 as mono-ADP-ribosyltransferase but has provided no 
physiological substrates so far apart from histones and automodification (Kleine et al., 2008), leaving 
open a lot of questions concerning the reported mono-ADP-ribosylation by ARTD10. Therefore a 
screening method to identify substrates in an unbiased manner was sought and found in the form of 
Invitrogens ProtoArrays. These arrays consist of nitrocellulose glass slides with approximately 8000 
proteins spotted per slide. Optimization procedures are described in (Braczinsky, 2009), an example of 
which is shown in Figure 13A where nitrocellulose slides were loaded with ARTD10 or histones as 
positive controls and BSA or GST as negative controls (modified from (Braczinsky, 2009)). The 
nitrocellulose slides were incubated with tandem affinity purified (TAP)-ARTD10 and biotin-NAD
+
 
or biotin-NAD
+
 only to test whether ARTD10 can modify immobilized substrates with biotin-NAD
+
 
(Braczinsky, 2009).  
 
 
Figure 13 Overview of the ProtoArray approach. (A) Nitrocellulose membranes with spotted ARTD10, core histones, 
BSA and GST were employed by A. Braczynski to optimize array conditions. Modified from (Braczinsky, 2009). (B) 
Schematic representation of ProtoArray screens. Each array was incubated with ARTD10, ARTD8 or BSA and 25 μM 
biotin-β-NAD+ and visualized using streptavidin-AlexaFluor647. 
 
These experiments indicate that ARTD10 is capable of modifying immobilized proteins with biotin-
NAD
+
, since the positive control H2B is only modified in presence of TAP-ARTD10. ADP-
ribosylation assays using biotin-NAD
+
 can thus be performed on these slides, upon which the 
incorporated mono-ADP-ribosylation can be detected by incubating with streptavidin-AlexaFluor647 
(Figure 13B). A similar approach was used to investigate putative ARTD8 substrates. Instead of TAP-
protein, baculo-derived ARTD8 was used. 
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Figure 14 Sub-arrays showing individual hits for ARTD10 and ARTD8. The upper panels show the location of GSK3β 
on both arrays, the middle panels show the modification of PDGFB on both arrays and the lower panels show PCCA on both 
arrays. In the middle a magnification of the relevant spots is shown.  
 
Exemplary sub-arrays are displayed, with spotted controls highlighted in white (Figure 14). When 
investigating these sub-arrays, it becomes clear that ARTD10 is stickier than ARTD8 and thus causes 
a higher background signal. It only sticks to the array surface however and not to spotted proteins, 
since most spots on the ARTD10 array appear blacker than the surrounding background. On of the 
sub-arrays displayed here contains the growth factor PDGFB, which apparently is a good ARTD10 
substrate. The modification of PCCA is also shown, which was identified on both arrays but is a 
biotin-binding enzyme, indicating that the signal is probably caused by biotin binding of PCCA and 
not by enzymatic modification by ARTD10 or ARTD8. GSKβ is being modified by ARTD10, 
although it appears to be only marginally above background. When compared to surrounding non-
modified spots instead of comparing to background levels however, the signal seems quite strong. To 
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be able to judge modification rates objectively, a Z-score is calculated for every protein. This Z-score 
is calculated by subtracting the population mean (μ) from the sample mean (χ), subsequently divided 
by the standard deviation of the population (σ). All proteins with Z-scores ≥ 2.5 are considered a hit 
and were taken into account for further analysis. 
 
Table 1: Top 30 ARTD10 substrates 
ProtoArray ID Uniprot ID Full name Z-score 
PHG0046 PDGFB_HUMAN Platelet-derived growth factor subunit B 28.0 
NM_000282.1 Q5JTW5_HUMAN 
Propionyl coenzyme A carboxylase, alpha 
polypeptide 20.9 
histone   Histone (unfractionated whole histone) 18.3 
Histone_F2a2   Histones H2A and H4 9.8 
PHC1244 CCL19_HUMAN Chemokine (C-C motif) ligand 19 9.7 
PHC0215 IL21_HUMAN Interleukin-21 9.4 
BC038838.1 PRR16_HUMAN Proline-rich protein 16 7.5 
BC012109.1 HOME2_HUMAN Homer protein homolog 2 7.0 
NM_020166.2 G5E9X5_HUMAN 
Methylcrotonoyl-coenzyme A carboxylase 1 
(alpha) 6.6 
NM_004113.3 FGF12_HUMAN Fibroblast growth factor 12 6 
PV3612 STK6_HUMAN Aurora kinase A 5.6 
PV3353 NEK6_HUMAN Serine/threonine-protein kinase Nek6 5.5 
PV4877 ACVR1_HUMAN Activin receptor type-1 5.3 
PV3270 GSK3A_HUMAN Glycogen synthase kinase alpha 5.1 
BC030711.2   C2orf13 5.0 
PV4883 ACVL1_HUMAN Serine/threonine-protein kinase receptor R3 4.9 
PV3501 PLK1_HUMAN Polo-like kinase 1 4.8 
NM_032459.1 EFS_HUMAN Embryonal Fyn-associated substrate 4.8 
PV3973 KGP2_HUMAN cGMP-dependent protein kinase 2 4.8 
NM_173597.1   Hypothetical protein FLJ37587 4.8 
PV3878 MARK2_HUMAN Serine/threonine-protein kinase MARK2 4.7 
PV3688 EPHA2_HUMAN Ephrin type-A receptor 2 4.7 
PHC1346 SDF1_HUMAN Stromal cell-derived factor 1 (CXCL12) 4.6 
PV3665 KC1D_HUMAN Casein kinase I isoform delta 4.6 
P2287 KPCD_HUMAN Protein kinase C delta type 4.6 
PHC1055 CCL5_HUMAN C-C motif chemokine 5 (RANTES) 4.5 
PV3826 CLK3_HUMAN Dual specificity protein kinase CLK3 4.4 
PHC0045 IL4_HUMAN Interleukin-4 4.4 
BC025700.1 AFF4_HUMAN AF/FMR2 family, member 4 4.2 
PV3365 GSK3B_HUMAN Glycogen synthase kinase beta 4.2 
 
In Table 1, a summary of the top hits identified on the ARTD10 arrays is given. After taking a first 
glance at the results, what becomes obvious is the presence of core histones amongst the top hits, 
thereby validating the previous studies and giving a first impression of reliability of the arrays. 
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Secondly, the presence of biotin-binding enzymes such as propionyl coenzyme A carboxylase alpha 
polypeptide (PCCA) and methylcrotonoyl-Coenzyme A carboxylase 1 alpha (MCCA) (Figure 14) 
among the top-hits implies that the spotted proteins are in a native state and able to bind biotin-NAD
+
. 
The measured signal for ARTD7 is probably automodification. Interesting is also that 3 of the proteins 
within the top 20, namely Never in mitosis A-related kinase 6 (NEK6), Aurora kinase A and Polo-like 
kinase (PLK1), are mitosis-related, implying that ARTD10 could regulate mitosis through these 
substrates. The growth arresting effect of ARTD10 in colony formation assays might be caused by 
modification of these substrates, possibly leading to disturbed mitosis. Before speculating on possible 
functions of the substrates identified however, it has to be validated that these proteins can indeed be 
modified by ARTD10 and ARTD8 in in vitro ADP-ribosylation assays and not merely represent some 
kind of artifact. 
 
To validate the results shown in Table 1, several substrates were tested in independent ADP-
ribosylation assays. Protein bought from Invitrogen was tested, IKKε and P-TEFb among the proteins 
tested as well as the cyclin-dependent kinase CDK5 (Figure 15A and B). Unfortunately, the P-TEFb 
protein preparation by Invitrogen proved insufficiently pure to distinguish whether CDK9 or Cyclin T 
is being modified by ARTD10. It is tempting to speculate that Cyclin T is substrate, since the protein 
band is not visible in coomassie staining but nevertheless a relatively strong ADP-ribosylation signal 
is present (Figure 15A). Alternatively, both might be modified by ARTD10, which has to be cleared in 
future studies with better protein preparations. Furthermore a panel of kinases, kindly provided by 
Stefan Knapp (Structural Genomics Consortium, Oxford, UK), was tested (Figure 15C). Interestingly, 
some of these proteins had a Z-score below 2.5, namely DYRK1, FES and SRPK2, which in this in 
vitro assay could be modified by ARTD10 nevertheless. This implies that by lowering the ProtoArray 
hit threshold from Z≥2.5 to for instance Z≥2.0, one could even increase the list of potential substrates. 
The kinase domain of cytoplasmic tyrosine-protein kinase BMX is not substrate, indicating that the 
modification site of this protein lies outside of the kinase domain. The growth factor PDGF-B was 
previously validated, as well as the kinase GSK3α (Feijs, 2009). Modification of the voltage-gated 
channel KCNAB1 immunoprecipitated from HeLa cells also takes place (Figure 15D) although to a 
lower extent and barely visible without enhancing contrast.  
 
Results | Identification of novel substrates of ARTD10 and ARTD8 
 
56 
 
Figure 15 Validation of ProtoArray results. ADP-ribosylation assays were performed on (A) recombinant P-TEFb (B) 
recombinant BMX kinase domain and CDK5 (C) recombinant ACVR1, BMX kinase domain, BSA, DYRK1A, FES, FES 
kinase domain, GST and SRPK2 (D) immunoprecipitated HA-GSK3β and HA-KCNAB1 from transiently transfected HeLa 
cells 
 
This might possibly be due to endogenous mono-ADP-ribosylation of the protein that currently cannot 
be assessed because of lacking tools to detect mono-ADP-ribosylation. Once hydrolases are identified 
that remove mono-ADP-ribose from substrates, one could treat immunprecipitated proteins with these 
hydrolases to remove all possible endogenous mono-ADP-ribosylation and test whether 
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immunoprecipitated proteins become a better substrate then. Alternatively, there could be other 
posttranslational modifications present that block efficient ADP-ribosylation by ARTD10. The last 
possibility might also be interference of the immunoprecipitation procedure with subsequent ADP-
ribosylation assays, where for instance the antibody might get in the way. 
The modification of proteins from different sources however excludes the possibility of false positive 
hits due to the technical artifacts in Invitrogen’s protein purifications. Since all tested full-length 
proteins could be verified as substrate, it can be assumed that the arrays are valid and the proteins 
identified true substrates, at least in in vitro assays. 
 
To analyze the similarities between the ARTD10 and ARTD8 substrate sets, a Venn diagram was 
made which shows that there is some overlap between ARTD10 and ARTD8 substrates, although both 
have a substantial amount of unique substrates (Figure 16A). This hints at roles in some different 
processes for the two enzymes although partially redundant. That only a relatively small amount of the 
8000 proteins on the array could be modified by ARTD8 and ARTD10 indicates that these enzymes 
are rather specific and probably function only partially redundant whilst having unique roles in certain 
processes. 
 
 
Figure 16 Analysis identified ARTD8 and ARTD10 substrates. (A) Venn diagram showing the overlap between the 
ARTD8 and the ARTD10 substrate sets. (B) ARTD10 substrates sorted according to function (C) Bioinformatical analysis 
revealed that the displayed motif appears more often in the positive hits than in the negative proteins (in collaboration with A. 
Schuppert). 
 
ARTD8 activates STAT-dependent gene expression upon IL-4 stimulation (Goenka and Boothby, 
2006; Goenka et al., 2007; Mehrotra et al., 2011) and it also protects B-cells from apoptosis by 
regulating key players in apoptosis, such as caspase-3 (Cho et al., 2009). Recently ARTD8 was 
described to be necessary for full pro-survival signaling by IL-4 in B-cells. Inhibition of AMP-
activated protein kinase (AMPK) disturbed IL-4 induced cell survival and glycolysis, activation of 
AMPK in Artd8-null cells sufficed to restore IL-4 mediated signaling (Cho et al., 2011). Together, 
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these reports hint at a role of ARTD8 in lymphoma survival and regulation of cellular metabolism and 
glycolysis. Gene ontology analysis of the ARTD8 substrates identified reveals that several substrates 
are involved in insulin signaling, such as insulin receptor substrate 1 (IRS1) and protein kinase c zeta 
(PRKCZ), through which glycolysis can be influenced. Death-associated protein kinase 1 and 3 
(DAPK1 and DAPK3) are two of the identified substrates that directly link ARTD8 with apoptosis. So 
far, the role of ARTD8 in apoptosis and metabolism has been investigated mainly in a descriptive 
manner. The underlying mechanisms might be uncovered by further analysis of the substrates 
described here. 
 
We focused on the ARTD10 substrate-set for further analysis and summarized the functions of the 
identified proteins (Figure 16B). It becomes apparent that the kinases seem to be overrepresented as 
substrate, as well as secreted factors. The high amount of growth factors as well as the top outlier 
being a growth factor might urge to further invest the functional consequence of mono-ADP-
ribosylation for this subclass of ARTD10 substrates. At the moment it is however not clear where and 
when ARTD10 and those growth factors could get in near proximity in cells. It is not possible yet to 
distinguish whether the identified growth factors are an artifact caused by the non-physiological 
conditions of the arrays, in which ARTD10 is capable of modifying any residues sticking out far 
enough or whether there are as yet unknown physiological processes wherein ARTD10 modifies 
growth factors. ARTD10 could for example have a role to play in non-conventional protein secretion 
such as an autophagy-based secretion pathway (Dupont et al., 2011), especially considering the fact 
that ARTD10 interacts with autophagy-adaptor protein p62 (Kleine et al., 2012). Or ARTD10 might 
be released into the extracellular matrix itself, perhaps from dying cells, or maybe even in a more 
regulated manner after inflammasome activation (Gross et al., 2011). Evidence for extracellular ART 
activity already exists in the form of release of other enzymatically active ADP-ribosyltransferases 
from activated T-cells (Kahl et al., 2000). It is a fascinating question nevertheless what happens to 
these growth factors once modified. Are they still able to bind to their receptors or is their receptor 
affinity changed? It has already been described that extracellular arginine-ADP-ribosylation of PDGF-
B by ARTC1 leads to a reduced receptor binding capacity (Saxty et al., 2001). 
 
ARTD10 apparently has quite strict substrate preferences, since it only modifies a small percentage of 
the 8000 proteins present on the ProtoArrays. We therefore asked whether there is a similarity 
between the positive hits that appears less frequent in the negative proteins. Informatics students 
without extensive molecular biology knowledge performed this bioinformatical analysis, thereby 
making this study completely unbiased (Bayer et al., 2011). Several motifs could be identified that are 
enriched in the positive hits and that can be summarized as K/RxxE/DxG (Figure 16C). Interestingly, 
the DFG-motif was identified before as general kinase motif, containing residues essential for catalytic 
activity (Kornev et al., 2006). It is not clear whether this motif was identified here because of the high 
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representation of kinases within the substrate group or because ARTD10 modifies one of the residues 
in this motif, thereby causing so many kinases to be substrate. The high presence of kinases and 
associated kinase motifs might actually mask the presence of other motifs that might be more relevant 
for ARTD10 substrate recognition. If on the other hand ARTD10 recognizes and modifies amino acids 
in this motif, then mono-ADP-ribosylation could represent an important general regulator of kinase 
activity. 
 
Since it is currently not clear whether ARTD10 can modify growth factors in cells, we decided to 
focus on the large substrate class of kinases and selected GSK3β as model kinase for tests of the 
functional consequences of mono-ADP-ribosylation. Through GSK3β a link is also established to the 
protein that ARTD10 originally was purified with, MYC (Yu et al., 2005). Phosphorylation of MYC 
on T58 by GSK3β leads to its activation, but also ubiquitination and subsequent degradation as 
reviewed in (Adhikary and Eilers, 2005; Vervoorts et al., 2006). Finally, GSK3β was not a substrate of 
ARTD8 on the ProtoArrays, making it more likely that putative functional consequences are really due 
to ARTD10 catalyzed mono-ADP-ribosylation and not to ARTD8. 
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mono-ADP-ribosylation of GSK3β regulates kinase activity 
Bacterially purified GST-GSK3β was tested as substrate (data not shown) and could be verified 
although weakly, but these protein preparations showed high amounts of breakdown products. Using 
the GateWay cloning technology, expression vectors suitable for the baculoviral system were created 
with as starting point the pcDNA3.1-HA-GSK3 acquired from Addgene (He et al., 1995). The 
pBAC-GST-GSK3 vector was transfected into SF9 cells, subsequent rounds of virus amplification 
were performed until the virus titer was suitable for final infection and protein purification. Staining 
with a specific antibody revealed that the protein binding to the beads indeed is GSK3β and that only 
small amounts of protein are lost during purification (Figure 17A).  
 
 
Figure 17 Purification and characterization GST-GSK3β. (A) Small-scale GST-purification, where boiled GST-beads, 
pellet and supernatant of pellet incubation were tested in WB for GSK3β presence. Left panel; specific α-GSKβ staining, 
right; Ponceau staining. (B) Coomassie staining of a large-scale purification, with a BSA standard ranging from 2μg to 0.1μg. 
(C) Increasing amounts of GSK3β were titrated in an in vitro kinase assay, incorporated radioactivity was assessed by 
scintillation counting.  
 
The quality and quantity of the protein in the two elution fractions was analyzed by coomassie blue 
staining (Figure 17B). Additionally, mass spec analysis (data not shown) also confirmed the purified 
protein as GSK3β. Lastly, its kinase activity was determined using kinase assays with radioactively 
labeled ATP and a primed substrate peptide (Figure 17C), where it becomes clear that the purified 
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protein is highly active and that small kinase amounts are best for enzymatic assays, as not to reach 
saturation too quickly. 
 
When tested in an ADP-ribosylation assay with TAP-ARTD10, baculo-purified GST-GSK3β could 
indeed be mono-ADP-ribosylated, whereas the negative control, GST could not (Figure 18A). An 
interesting side note is that ARTD10 seems to have differing affinities for GSK3β purified from 
different sources. The most intense signal is achieved in an ADP-ribosylation assay with baculo-
derived GST-GSK3β, whereas GST-tagged GSK3β purified from E.coli is modified less well. GST-
GSK3β purified from E.coli has kinase activity, although to a lower extent, so apparently it is folded 
correctly. It is tempting to speculate that baculo-derived GSK3β carries some modification that 
increases the affinity of ARTD10 towards it. Examples of enzymes only recognizing proteins when 
these have certain PTMs already exist, such as described above for the E3 ligases Iduna or SCF
FBW7
. 
HA-GSK3β immunoprecipitated from HeLa cells is also a rather weak substrate (Figure 15D), 
indicating that the protein already is mono-ADP-ribosylated, lacks the right PTM or maybe carries a 
PTM that blocks efficient ADP-ribosylation by ARTD10.  
 
 
Figure 18 GSK3β is mono-ADP-ribosylated by ARTD10 and interacts with ARTD10. (A) ADP-ribosylation assay with 
TAP-ARTD10 and GST-GSK3β or GST, analyzed by coomassie and autoradiography. (B) GST-pull down experiment 
between TAP-ARTD10 and GST-GSK3β. The blot was cut in two, the upper piece was incubated with an ARTD10 
antibody, the lower part was incubated with a GST antibody. 
 
GST-pull down experiments show a weak interaction between TAP-ARTD10 and GST-GSK3β 
although above background, that is not dependent on ATP or NAD
+
 (Figure 18B). 
 
Next we addressed whether mono-ADP-ribosylation in any way influences the enzymatic activity of 
GSK3β, although no direct effects of mono- or poly-ADP-ribosylation have been described for 
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proteins modified by eukaryotic enzymes so far. For this purpose GST-GSK3β was mono-ADP-
ribosylated by TAP-ARTD10 and then tested in an in vitro kinase assay using a synthetic peptide 
carrying a priming phosphate. The kinase activity of mono-ADP-ribosylated GSK3 activity was 
significantly reduced, in contrast to incubation of GSK3β with TAP-ARTD10 in the absence of β-
NAD
+
 or with the catalytically inactive mutant ARTD10-G888W, which resulted in a small increase 
in activity (Figure 19A). 
 
 
Figure 19 Mono-ADP-ribosylation inhibits GSK3β activity in vitro but not P-TEFb activity. (A) GSK3β was mono-
ADP-ribosylated with β-NAD+ and subsequently activity was assessed in a kinase assay with a substrate peptide and [32P]-γ-
ATP. Incorporated radioactivity was determined by scintillation counting. Data are represented as mean ±SD of a 
representative experiment with triplicate measurements. (B) Assays performed as in (A) but with P-TEFb instead of GSK3β. 
Preliminary data from one experiment are displayed. (C) Increasing amounts of substrate were titrated in an in vitro kinase 
assay with untreated or mono-ADP-ribosylated GSK3β, incorporated radioactivity was assessed by scintillation counting. 
Error bars represent SD of quadruplicate measurements a representative experiment is shown. 
 
Phosphorylations in the activation loop determine the structural localization of the aspartate of the 
DFG motif, necessary for an active kinase (Kornev et al., 2006). If ARTD10 modifies a site in this 
area, ADP-ribosylation might thus prevent the proper conformation and thereby block catalytic 
activity. Moreover, since the kinase purified from E.coli will lack the phosphorylation at this site and 
thus have the DFG-motif in a closed conformation already, this might be the wrong conformation to 
allow efficient modification by ARTD10 and thereby explain why GSK3β from SF9 cells is a better 
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substrate than GSK3β. The differences between the GSK3β from different sources could be tested 
using mass spec to investigate whether there indeed are different PTMs that might influence 
recognition by ARTD10. 
 
In contrast, when subjecting P-TEFb to similar experiments, no effect on kinase activity could be 
measured in a preliminary experiment (Figure 19B), implying that either modification is not taking 
place efficiently enough or that mono-ADP-ribosylation has a different effect on this cyclin/CDK 
complex. This could be due to the fact that the cyclin subunit might be modified and not the kinase, 
which has to be clarified in future studies, where it for instance could also be addressed whether 
mono-ADP-ribosylation of P-TEFb influences binding of the different subunits to each other or to 
different proteins like MYC, which it has been shown to bind to (Kanazawa et al., 2003). 
Alternatively, intracellular localization of the P-TEFb subunits might be influenced by mono-ADP-
ribosylation, as has been described for other PTMs of P-TEFb (Dow et al., 2010). 
 
Serine 9 phosphorylation of GSK3β functions as competitive inhibitor of enzymatic activity (Frame et 
al., 2001), since the tail folds back onto the kinase domain as pseudo-substrate and blocks the catalytic 
site in this manner (Figure 1). To investigate whether mono-ADP-ribosylation functions in a manner 
comparable to serine 9 phosphorylation, substrate amounts were titrated in in vitro kinase assays. In 
the case of competitive inhibition, sufficient amounts of substrate will lead to increased kinase activity 
despite inhibitor since the substrate will then effectively compete with the pseudo-substrate for 
binding in the catalytic center. The graph in Figure 19C shows that initially non-modified GSK3β 
shows a higher activity than mono-ADP-ribosylated GSK3β as expected. The increasing amounts of 
substrate do not suffice to abolish the inhibitory effect of mono-ADP-ribosylation, as even high 
amounts of substrate do not restore kinase activity to a level comparable to non-modified GSK3β, 
indicating a non-competitive inhibitory mechanism. Since serine 9 phosphorylation functions as 
competitive inhibitor, the here reported inhibitory mechanism is proposed to be distinct from the 
inhibition caused by serine 9 phosphorylation and thus represents a novel regulatory mechanism. 
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Figure 20 Mono-ADP-ribosylation inhibits GSK3β activity in cells. (A) GFP-ARTD10 or the inactive mutant GFP-
ARTD10-G888W were co-expressed with HA-GSK3β in U2OS cells. Immunoprecipitated GSK3β was subsequently 
subjected to an in vitro kinase assay. Data are represented as mean ±SEM of biological triplicates.  (B) Input controls for (A). 
(C) U2OS cells were treated with siARTD10 or siControl pools, endogenous GSK3β was immunoprecipitated, subjected to 
kinase assays and evaluated with scintillation counting. Data are represented as mean ±SEM of biological triplicates. (D) 
Input controls for (C). (E) U2OS cells transfected with siRNA pools were mock- or IFNα-treated 24 hours after transfection, 
lysed after 48 hours, endogenous GSK3β was immunoprecipitated, subjected to kinase assays and evaluated with scintillation 
counting. Preliminary data from one experiment are shown. (F) Input controls for (E).  
 
Previous studies using colony formation assays have revealed that overexpression of ARTD10, but not 
ARTD10-G888W, interferes with cell proliferation (Kleine et al., 2008), suggesting that mono-ADP-
ribosylation occurs in cells and is vital for normal cell physiology. To expand on this observation, we 
co-expressed GFP-ARTD10 or GFP-ARTD10-G888W together with HA-GSK3β in U2OS cells and 
subsequently determined kinase activity of immunoprecipitated GSK3β. Kinase activity was decreased 
with co-expression of ARTD10 compared with control-transfected cells (Figure 20A), indicating that 
ARTD10 indeed intracellularly mono-ADP-ribosylates GSK3β. In contrast, co-expression of 
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ARTD10-G888W induced kinase activity, which might be due to a dominant-negative effect of the 
catalytically inactive ARTD10 and thus hints at the presence of endogenous mono-ADP-ribosylation 
of GSK3β. The effects were not the result of altered GSK3β expression or of different 
immunoprecipitation efficiencies (Figure 20B).  
 
To exclude artifacts caused by protein overexpression, we additionally knocked down ARTD10 with 
siRNA SMARTpools in U2OS cells, immunoprecipitated endogenous GSK3β and tested kinase 
activity. Knockdown of ARTD10 was efficient and indeed led to a significant increase in kinase 
activity (Figure 20C), thereby again hinting at endogenous ADP-ribosylation. The differences in 
kinase activity were not caused by influences of siRNA on GSK3β levels, since the input blots show 
comparable levels of GSK3β in siControl and siARTD10 treated cells (Figure 20D). 
 
To test in a preliminary experiment whether IFNα indeed induces ARTD10 expression as reported, 
cells transfected with siControl or siARTD10 were stimulated with IFNα for 24 hours, as ARTD10 
was indicated as late-response gene (Mahmoud et al., 2011). ARTD10 protein expression is only 
upregulated in the siControl-transfected cells and not in the siARTD10-transfected cells, indicating 
that IFNα indeed upregulates ARTD10 gene transcription (Figure 20F). Moreover, IFNα seems to 
have an inhibitory effect on GSK3β activity, indicating that upon upregulation of ARTD10, it 
modifies a larger amount of GSK3β and thereby blocks kinase activity (Figure 20E). IFNα has no 
effect on GSK3β activity in the siControl-transfected cells. 
 
Further validating these findings, we measured the phosphorylation of p65 RELA at S468, a known 
GSK3β target as schematically represented in Figure 21A (Buss et al., 2004). ARTD10-G888W 
overexpression and knockdown of endogenous ARTD10 by shRNA enhanced p65-S468 
phosphorylation (Figure 21B), supporting the concept that mono-ADP-ribosylation of GSK3β by 
ARTD10 inhibits kinase activity in cells. Overexpressed HA-GSK3β is efficiently phosphorylated at 
serine 9, explaining why overexpression of HA-GSK3β does not suffice to induce p65-S468 
phosphorylation to the same extent. 
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Figure 21 Mono-ADP-ribosylation influences GSK3β downstream signaling. (A) Schematic representation of GSK3β 
and p65 inhibitory phosphorylations. Modified from (Buss et al., 2004). (B) ARTD10 was knocked-down using shRNA or 
overexpressed in U2OS cells, as well as ARTD10-G888W or HA-GSK3β. 48 hours after transfection cells were lysed and 
the proteins analyzed on Western Blot. A representative blot is shown. 
 
Although this is only indirect proof of intracellular mono-ADP-ribosylation, because of the lack of 
antibodies or other detection tools, this is currently the best evidence of intracellular ARTD10 activity 
that can be achieved. That mono-ADP-ribosylation can directly influence the activity of a substrate 
implies a functional difference between poly- and mono-ADP-ribosylation, because poly-ADP-
ribosylation so far has mainly been reported to influence signaling events through recruitment of other 
proteins, such as ubiquitin E3 ligases (Gibson and Kraus, 2012), but not through a direct regulation of 
enzymatic activity of substrate proteins. PAR chains might actually also be capable of influencing 
proteins directly, but we might just not be aware of it yet. In contrast to serine 9 phosphorylation, this 
inhibitory mechanism seems to be non-competitive and thereby opens a novel dimension in GSK3β 
regulation. It is tempting to speculate that different stimuli might lead to different ways of inhibition of 
GSK3β, thereby directing GSK3β activity to certain pathways under specific circumstances, as has 
been described before in e.g. regulation of Wnt signaling (McNeill and Woodgett, 2010).  
 
The transcription factor MYC should also be influenced by altered GSK3β activity, as schematically 
summarized in Figure 22A. Decreased phosphorylation by GSK3β should lead to decreased 
ubiquitination and increased stability of MYC, because the recognition site for SCF
FBW7
 is dependent 
on this phosphorylation as described in the introduction. In vivo ubiquitination experiments reveal no 
such effect on MYC ubiquitination, which seems to be not influenced by ARTD10 co-expression 
(Figure 22B). However, these experiments were performed in the absence of any proteasome inhibitor, 
which should lead to a degradation of the K48-linked MYC modified by SCF
FBW7
, indicating that it 
likely is K63-linked polyubiquitin that is present in the pull-down. Any effects on K48-linked 
ubiquitination could be masked by strong K63-linked ubiquitin signals. Experiments performed with a 
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proteasomal inhibitor have a similar outcome, which may indeed be caused by a strong K63-linked 
polyubiquitination (data not shown). To avoid the difficulties with K63-linked ubiquitin masking K48-
linked ubiquitin signals, MYC activity was next tested in reporter gene assays. Here it could indeed be 
shown that ARTD10 co-expression negatively influences MYC activity (Figure 22C), which is in 
accordance with lower kinase activity and thus less T58 phosphorylation, which is not only a signal 
for degradation through ubiquitination but also for activation (Vervoorts et al., 2006). It is however 
also possible that ARTD10 affects MYC activity not through GSK3β, but via one of its other 
substrates, such as P-TEFb (Gargano et al., 2007; Kanazawa et al., 2003), or also directly through the 
protein-protein interaction published before (Yu et al., 2005).  
 
HECTH9 is an E3-ligase ubiquitinating MYC with K63-linked polyubiquitin, not leading to 
degradation of MYC but to activation (Adhikary et al., 2005). In the reporter gene assay, 
overexpressed MYC can indeed be further activated by co-expression of HECTH9 (Figure 22C). 
ARTD10 and the inactive mutant ARTD10-G888W are capable of repression also in the presence of 
HECTH9. A double mutant, where the UIMs are inactivated and catalytic activity is blocked, 
ARTD10-G888WdUIM, has no repressive effect anymore, suggesting that ARTD10 might be 
recruited through its UIMs and inhibit MYC by binding to it in addition to the necessity of catalytic 
activity. In vitro pull-down assays were used to narrow-down the region of MYC interaction within 
ARTD10, but due to stickiness of in vitro translated MYC, MYC signals were present after incubation 
with 5 different ARTD10 fragments (data not shown) and since this was not the main focus of the 
study presented here, further attempts at unraveling the relation between MYC and ARTD10 were 
abandoned for the time being.  
 
However, future experiments could address the role of endogenous ARTD10 in MYC regulation by 
inducing ARTD10 expression by IFNα and assessing endogenous MYC-responsive genes by rt-PCR 
or in reporter gene assays. 
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Figure 22 ARTD10 has no influence on MYC ubiquitination but represses reporter gene activity. (A) Schematical 
representation of the different signals leading to MYC phosphorylation and ubiquitination. Modified from (Adhikary and 
Eilers, 2005). (B) U2OS cells were transfected with His-ubiquitin, Flag-MYC and HA-ARTD10. Upon urea lysis, a pull-
down was performed with TALON™ Metal Affinity Resin followed by a WB. Upper panel displays the input controls, lower 
panel displays the pull-down, where the upper part was incubated with an ARTD10 antibody and the lower part with an 
MYC antibody. A representative blot is shown. (C) Reporter gene assay in U2OS cells, where the influence of indicated 
proteins was tested on an artificial luciferase construct with multiple MYC-binding sites (n≥3). 
 
An interesting additional observation in the in vivo ubiquitin assays is that ARTD10 itself is also 
pulled-out with TALON™ Metal Affinity Resin from cells containing His6-ubiquitin, indicating that 
ARTD10 is also ubiquitinated under these circumstances (Figure 22B). This is probably also not K48-
linked ubiquitin, since the protein carrying this would have been degraded quickly in the absence of 
proteasome inhibitor. 
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These findings highlight the possible effects of mono-ADP-ribosylation on GSK3β activity towards its 
substrates in cells, the full extent to which GSK3βs activity is altered towards its vast array of 
substrates remains to be assessed. Since GSK3β has already been described to be present in different 
intracellular pools depending on different stimuli (Taelman et al., 2010), it might well be that 
substrates of one GSK3β pool are influenced whereas others are not. This could be an explanation of 
the negative influence of ARTD10 on p65 phosphorylation but the lack of effect on MYC 
ubiquitination. If ARTD10 mono-ADP-ribosylates only cytoplasmic GSK3β, then it might be 
expected that phosphorylation of MYC by GSK3β is not influenced. Another key aspect in this regard 
is the priming phosphate preference of GSK3β that might actually be more limiting in some cases than 
GSK3β activity itself. It could theoretically happen that GSK3β becomes more active after inhibition 
of ARTD10, but if priming phosphates are lacking then increased GSK3β activity will not be seen on 
these substrates. Future research will have to reveal which GSK3β substrates can be influenced 
through manipulation of ARTD10. 
 
Since multiple reports agree on a growth-inhibitory effect of ARTD10 (Chou et al., 2006; Kleine et 
al., 2008), colony formation assays were performed to test whether overexpression of the hyperactive 
mutant HA-GSK3β-S9A can restore proliferation rates of cells with increased ARTD10 levels. 
 
 
Figure 23 Colony formation assay with HA-ARTD10 and HA-GSK3β-S9A. HA-ARTD10 and HA-GSK3β-S9A were 
transfected into HeLa cells in addition to a puromycin control vector, transfected cells were selected by puromycin treatment. 
A representative experiment is shown. 
 
HA-ARTD10 inhibits cell proliferation in this assay in accordance with published findings, however 
HA-GSK3β-S9A co-expression does not suffice to restore the colony formation potential (Figure 23). 
This indicates that probably other ARTD10 substrates are responsible for the growth inhibitory 
phenotype or alternatively that the overexpressed S9A-mutant can also be mono-ADP-ribosylated very 
efficiently and thus is not able to overcome the inhibition of activity induced by ARTD10. 
Alternatively, the overexpression of an hyperactive GSK3β mutant itself might inhibit proliferation, as 
colony formation seems to be reduced compared to control cells. 
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de-ADP-ribosylation by MDO2 restores GSK3β activity 
Regarding the impact of mono-ADP-ribosylation on GSK3β, it can be hypothesized that this 
modification is reversible, comparable with e.g. reversibility of phosphorylation mediated by 
phosphatases. To test this hypothesis, GSK3β was first mono-ADP-ribosylated in vitro and 
subsequently subjected to treatment with diverse potentially de-ADP-ribosylating enzymes.  
 
 
Figure 24 ARTD10 and GSK3β can be de-ADP-ribosylated by MDO2 but not mMacro1, mMacro2 or ARH1. (A) 
Mono-ADP-ribosylated TAP-ARTD10 and GST-ARTD10-G888W were subjected to MDO2, Macro1 and Macro2 treatment. 
(B) Mono-ADP-ribosylated TAP-ARTD10 and GST-GSK3β were subjected to His-MDO2 treatment. (C) Mono-ADP-
ribosylated TAP-ARTD10, GST-GSK3β and GST-ARTD10-G888W were subjected to ARH1 or ARH1D60, 61A treatment.  
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As expected, Macro1 and Macro2 of Artd8 cannot hydrolyze mono-ADP-ribose (Figure 24A), which 
also fits with the description of these Macrodomains as mono-ADP-ribose binding modules (Forst et 
al., manuscript in revision). His-purified His-GST-MDO2 however is capable of removing the ADP-
ribose moiety from GSK3β and also from ARTD10 itself (Figure 24B). This is quite surprising, as 
MDO2 has previously been described to hydrolyze O-acetyl-ADP-ribose only (Chen et al., 2011). No 
hydrolase activity of MDO2 towards ADP-ribosylated proteins has been shown before. In contrast to 
this, the arginine-specific ARH1 (kind gift from J. Moss, NIH, Bethesda, USA) is also not capable of 
removing ADP-ribose from either ARTD10 itself or from GSK3β as expected (Figure 24C). Since the 
described substrate preference for ARH1 are mono-ADP-ribosylated arginines (Takada et al., 1993), 
this would also fit to the model of substrate-assisted catalysis wherein acidic residues form the 
acceptor site. Modeling suggests that MDO2 can only remove ADP-ribose from acidic residues 
(Rosenthal, Feijs et al., manuscript in revision), implying that GSK3β is indeed modified on a 
glutamate or aspartate, as the current model of substrate-assisted catalysis also suggests.  
 
 
Figure 25 MDO2 mutants have different catalytic activies. GST-GSK3β was coupled to beads and ADP-ribosylated, 
followed by an incubation with indicated MDO2 proteins and analysis by SDS-PAGE and autoradiography. 
 
These models imply that at least 4 residues, D102, H106, Y140 and T144, in MDO2 are necessary for 
binding of the ADP-ribose and are potentially involved in hydrolysis. The activity of these mutants 
towards TAP-ARTD10 and GST-GSK3β was tested and indeed, those mutants display a lower 
hydrolyzing activity in a preliminary experiment (Figure 25). However, extensive kinetics are needed 
to assess the exact influence of each mutation on activity. 
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To narrow down the range of possible amino acids that are modified by ARTD10 and thereby support 
the generated models of MDO2 de-ADP-ribosylating acidic residues and the substrate-assisted 
catalysis of ARTD10 using glutamates (Kleine et al., 2008), HA-ARTD10-ΔK was overexpressed in 
HeLa cells. ARTD10-ΔK is a mutant in which all lysines are substituted with arginines. Lysines were 
considered as acceptor site because lysines have been identified as ARTD1 automodification site 
(Altmeyer et al., 2009) and also as acceptor site in histones (Messner et al., 2010). The underlying 
hypothesis for the ARTD10-catalyzed modification would be that the substrates’ glutamate or 
aspartate stabilizes the oxacarbenium transition state as described in the introduction, but that a 
neighboring lysine would serve as final acceptor. This has not been shown so far, but would 
theoretically be a possibility. HA-ARTD10-ΔK was immunoprecipitated and subsequently subjected 
to an ADP-ribosylation assay with radioactively labeled NAD
+
. After extensive washing of the beads 
with immunoprecipitated material, incubation with MDO2 followed. The automodification potential 
of this ARTD10 mutant is significantly lower than wildtype activity (Figure 26A) and it also modifies 
substrates to a much lower extent, as exemplified with GST-  (Figure 26B). This 
could possibly be due to the fact that two of the mutated lysines are directly at the catalytic cleft, 
where even a single point mutation might render the protein less active or even inactive. Modification 
of ARTD-ΔK by GST-ARTD10(818-1025) takes place at a rate comparable with modification of the 
inactive ARTD10-G888W mutant, indicating that the overall structure of the protein is still intact 
(Figure 26A). It can still automodify to a certain extent and importantly, wildtype MDO2 can remove 
this modification (Figure 26C). The point mutant MDO2-G100E represents a typical Macrodomain 
mutant in which the catalytic site is blocked, thereby making hydrolysis impossible. This mutant is 
indeed not capable of removing the mono-ADP-ribose from HA-ARTD10-ΔK. These data indicate 
that MDO2 indeed de-ADP-ribosylates other amino acids than lysines. This makes it highly unlikely 
that ARTD10 modifies lysines, especially when taking into account that no dual specificities have 
been reported for ARTDs or hydrolases yet. Moreover, these data support the generated models of 
MDO2 as ADP-ribosylglutamate hydrolase. 
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Figure 26 MDO2 de-ADP-ribosylates ARTD10-ΔK. (A) HA-ARTD10, HA-ARTD-ΔK and HA-ARTD10-G888W were 
overexpressed in HeLa cells and immunoprecipitated. Subsquently ADP-ribosylation assays were performed to test 
automodification (left) or with addition of GST-ARTD10(818-1025) to test trans-modification. (B) HA-ARTD10 and HA-
ARTD10-ΔK were overexpressed in HeLa cells, immunoprecipitated and used to modify GSK3β in an ADP-ribosylation 
assay. (C) HA-ARTD10-ΔK was overexpressed in HeLa cells and immunoprecipitated. Subsequently ADP-ribosylation 
assays were performed, followed by washing of the beads and incubation with His-GST-MDO2 or His-GST-MDO2-G100E. 
 
These findings led us to test whether removal of mono-ADP-ribose by MDO2 is sufficient to restore 
GSK3β kinase activity. Mono-ADP-ribosylated GSK3β was incubated with MDO2 followed by a 
kinase assay. In this in vitro assay, de-ADP-ribosylation of GSK3β by MDO2 sufficed to restore 
kinase activity to levels comparable with unmodified control GSK3β (Figure 27). These findings 
imply that mono-ADP-ribosylation of GSK3β does not induce irreversible conformational changes. 
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Figure 27 de-ADP-ribosylation by MDO2 suffices to restore GSK3β activity in vitro. Mono-ADP-ribosylated GSK3β 
was incubated with MDO2, kinase activity was subsequently assessed in kinase assays. Incorporated radioactivity was 
determined by scintillation counting. Data are represented as mean ±SD of 3 measurements, a representative experiment is 
shown. 
 
Next, we tested whether MDO2 also counteracts ARTD10 in cells. HA-GSK3β was co-expressed with 
dsRed-ARTD10 alone or together with GFP-MDO2 and subsequently kinase assays were performed 
with the immunoprecipitated GSK3β. Overexpression of MDO2 itself stimulated kinase activity 
(Figure 28A), compatible with the experiments shown before using either ARTD10-G888W or 
shRNA against ARTD10, supporting the notion that GSK3β is mono-ADP-ribosylated in cells by 
endogenous ARTD10. Moreover MDO2 antagonized the activity of co-transfected ARTD10, without 
affecting protein expression as is shown in the input blot (Figure 28B). These effects seem rather 
small, possibly caused by lacking stimuli or by a suboptimal ratio of ADP-ribosyltransferase versus 
ADP-ribosylhydrolase and could possibly be further optimized. 
 
Co-expression of His-tagged ARH1 in contrast had no influence on GSK3β activity in a preliminary 
experiment (Figure 28C), as might be expected from the negative results in the in vitro assays. The 
overexpression levels are equal and do not lead to altered GSK3β levels (Figure 28D). This indicates 
that specific catalytic hydrolase activity is necessary to restore GSK3β to its non-ADP-ribosylated 
kinase activity and not merely some ADP-ribose hydrolyzing enzyme.  
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Figure 28 MDO2, but not ARH1 overexpression restores GSK3β activity. (A) dsRed-ARTD10 and GFP-MDO2 were co-
expressed with HA-GSK3β in U2OS cells. Immunoprecipitated GSK3β was subsequently subjected to a kinase assay and 
analyzed by scintillation counting. Data are represented as mean ±SD of three measurements, a representative experiment is 
shown. (B). Input controls for (A). (C) dsRed-ARTD10 and His-ARH1 were co-expressed with HA-GSK3β in U2OS cells. 
Immunoprecipitated GSK3β was subsequently subjected to a kinase assay and analyzed by scintillation counting. Preliminary 
data from one experiment are shown. (D) Input controls for (C). 
 
These results indicate that de-ADP-ribosylation of GSK3β is sufficient to restore kinase activity, 
meaning that ADP-ribosylation can function as on/off-switch for GSK3β.  Multiple additional 
questions arise. When is GSK3β ADP-ribosylated in cells, is some signal required to activate 
ARTD10 or to get the two proteins together under physiological conditions, without overexpressed 
protein? If e.g. IFNα can lead to increased ARTD10 protein expression (Figure 20F), will this then 
automatically lead to GSK3β inhibition or are additional signals necessary to bring the two proteins in 
the correct spatial vicinity? Or do the cells have high enough steady-state levels of MDO2 to 
efficiently counteract ARTD10?  
 
Since overexpression of HA-GSK3β-S9A fails to restore colony formation potential, colony formation 
assays were performed to test if co-expression of MDO2 suffices to restore the normal growth 
behavior of cells with overexpressed ARTD10. HA-ARTD10 leads to decreased colony formation as 
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expected from previous results, whereas HA-MDO2 does not influence cell proliferation in this type 
of assay (Figure 29). 
 
 
Figure 29 Colony formation assay with HA-ARTD10 and HA-MDO2. HA-ARTD10 and HA-MDO2 were transfected 
into HeLa cells in addition to a puromycin control vector, transfected cells were selected by puromycin treatment. Numbers 
in brackets indicate the relative amounts of DNA transfected. A representative experiment is shown. 
 
HA-MDO2 was titrated in the indicated amounts in addition to unchanged HA-ARTD10 transfection. 
None of the transfected amounts of HA-MDO2 can reverse the inhibitory effect of ARTD10, 
indicating that the relevant substrates are not accessible to HA-MDO2 or that the stalled cell growth is 
caused independent of catalytic activity. It is however highly unlikely that this effect is independent of 
catalytic activity because several inactive ARTD10 mutants do not cause this proliferation arrest 
(Schuchlautz, 2008). Since nothing is known about the intracellular localization of MDO2 yet, it is 
imaginable that for example the mitosis-related kinases such as NEK6 and PLK1 are modified by 
ARTD10 in a distinct cellular compartment, thereby influencing mitotic progression but being 
inaccessible for MDO2 because it does not localize to this compartment. To be able to investigate 
these different possibilities in more detail, His-GST-MDO2 was used as antigen to create antibodies, 
which are currently being tested (in collaboration with E. Kremmer). These antibodies will aid in 
future studies to answer questions concerning e.g. MDO2 localization. 
 
Taken together, these results indicate that mono-ADP-ribosylation is a PTM that can directly influence 
the modified proteins and that can be reversed in vitro as well as in cells. One of the questions that can 
be asked next, when considering the impact mono-ADP-ribosylation has on GSK3β kinase activity, is 
how ARTD10 activity is regulated in cells. 
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Phosphorylation of ARTD10 by GSK3 
No regulatory mechanisms have been identified for ARTD10 so far, it is currently unknown when the 
protein localizes to which cellular compartment, when it is active or when it is degraded. Taking a 
closer look at the identified substrates however (Table 1), it becomes apparent that the modification of 
so many different proteins has to be regulated tightly. In support of this notion is the severe effect that 
ARTD10 knockdown or overexpression has on cell proliferation (Chou et al., 2006; Feijs, 2009; 
Kleine et al., 2008). Upon entering of the ARTD10 sequence into the ELM Database (Dinkel et al., 
2012), multiple interesting eukaryotic linear motifs (ELM) can be identified (Figure 30). The ELM 
Database currently contains 1800 linear motifs and additionally provides the user with structural 
information on the entered sequence. Additionally, it can be assessed whether motifs identified are 
conserved throughout the species. A higher conserved motif has a higher likelihood of being relevant. 
These motifs can provide first hints at the diverse proteins binding to or modifying ARTD10. 
 
There are diverse motifs for kinases that can be identified in ARTD10 such as protein kinase A (PKA) 
and PLK1 motifs. This hints for instance at a reciprocal interaction between ARTD10 and PLK1, 
because PLK1 was identified in the ProtoArrays as ARTD10 substrate. Of particular interest are also 
the SCF
FBW7
, TRAF2 and TRAF6 motifs depicted, since ARTD10 is ubiquitinated in cells by an 
unknown E3 ligase and with thus far unknown consequence (Figure 22B) and is involved in NF-κB 
signaling (Verheugd et al., manuscript in revision). Considering the fact that TAP-ARTD10 becomes 
much less active upon dephosphorylation (Schuchlautz, 2008), the phosphatase motifs present in the 
catalytic domain could also prove to be important for regulation of ARTD10 activity. The areas 
marked in red are globular domains and thus less likely to be modified than the unstructured regions 
marked in green because many PTMs occur in unstructured regions, although for example acetylation 
does not occur more often in unstructured protein regions than in structured regions (Gao and Xu, 
2012). Moreover, SMART/Pfam domain analysis is integrated in this analysis. Interestingly, the ART 
domain is not recognized although 3 potential ubiquitin interaction motifs are found. 
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Figure 30 Overview of diverse linear motifs present in ARTD10. Sequence analysis was performed with the online ELM 
Database, which predicted the depicted eukaryotic linear motifs in ARTD10. A detailed description of the diverse motifs and 
their implications can be found at http://elm.eu.org 
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There are also putative GSK3 modification sites present in ARTD10, however one must keep in 
mind that the consensus motif for GSK3 is a very general one, S/T x x x pS/pT, and identified ELMs 
in a sequence might thus only be artificial. Over the years, the ELM Database has been improved to 
remove possibly artificial motifs (Dinkel et al., 2012; Gould et al., 2010) but nevertheless there are 
several GSK3β motifs present. GSK3β also phosphorylates other ARTD family members, such as 
ARTD5 (Yeh et al., 2006). 
 
To examine whether GSK3β is indeed capable of modification of ARTD10, a kinase assay was 
performed with GST-GSK3β, BSA as negative control or baculo-derived p65 (a kind gift from M.O. 
Hottiger, ETH Zurich, Switzerland) as positive control to optimize reaction conditions (data not 
shown). Autoradiography shows that GSK3β can modify TAP-ARTD10 under these circumstances 
(Figure 31A), implying that priming phosphorylations are either already present on the protein or that 
a non-primed phosphorylation site is being modified. To narrow down the area of modification, 
different overlapping GST-tagged fragments of ARTD10 (Figure 31B) were used in a kinase assay, 
where it becomes apparent that only fragment 3 can be modified in this in vitro assay (Figure 31C), 
indicating that the modification site lies between amino acids 459 and 600. Since these proteins were 
purified from E.coli, it can be assumed that no priming phosphorylation is present and this site thus 
represents a non-primed site. Mass spectrometry analysis of the phosphorylated fragment indicates 
threonine 553 as modification site, labeled in red in the surrounding sequence (Figure 31D). Marked in 
blue is a 14-3-3 binding motif identified using the ELM database, implying that phosphorylation by 
GSK3β might regulate 14-3-3 binding. Of course, this is very hypothetical as yet. It would have to be 
verified first that GSK3β can modify ARTD10 in cells and moreover no interaction of ARTD10 with 
14-3-3 proteins has been described yet. Additionally, intracellular GSK3β possibly modifies ARTD10 
at the sites indicated in Figure 30, for which the priming phosphorylations lack in the E.coli purified 
protein. 
 
Results | Phosphorylation of ARTD10 by GSK3β 
 
80 
 
Figure 31 GSK3β phosphorylates ARTD10 at T553. (A) A kinase assay was performed with GST-GSK3β and TAP-
ARTD10 or BSA. (B) Schematic representation of the different ARTD10 fragments generated to map the modification site in 
(C) A kinase assay was performed with GSK3β on TAP-ARTD10 and GST-fragments. (D) Mass spec analysis of 
phosphorylated fragment three revealed the presence of one phosphorylated peptide, the putatively modified threonine is 
marked in red. Depicted in blue is a putative 14-3-3 interaction motif. 
 
To test whether this phosphorylation influences ARTD10 activity, ARTD10 was phosphorylated with 
non-labeled ATP and subsequently tested in an ADP-ribosylation assay. Automodification is not 
altered by phosphorylation of threonine 553 by GSK3β in a preliminary experiment (data not shown), 
leaving the functional consequence of this phosphorylation open at the moment. GST-pull down 
experiments indicate that ATP and NAD
+
 are not absolutely necessary for the interaction of the two 
proteins (Figure 18B). Binding of GSK3β to ARTD10 seems to be relevant for catalytic activity in an 
as yet unexplained manner, causing us to further investigate the interaction between the two proteins. 
 
Previous experiments have already revealed the presence of multiple phosphorylation sites in 
ARTD10 (Schmitz, 2010), serine 324 was found to be phosphorylated in the G1-phase of the cell cycle 
by high-throughput mass spec analysis (Gnad et al., 2011; Olsen et al., 2010), ubiquitination of 
ARTD10 is taking place (Figure 22B) and acetylation of ARTD10 has been detected at lysine 916 also 
in proteome-wide high-throughput screening approaches (Choudhary et al., 2009). Future experiments 
will have to reveal not only the responsible enzymes but also when these modifications occur and 
what the functional relevance thereof is. 
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Bioinformatical models of ARTD10 with NAD+ and GSK3β 
To further define the interaction between ARTD10 and GSK3β, bioinformatical models were created 
(in collaboration with V. Lossaso and Prof. P. Carloni, GRS, Jülich, Germany). Since the only 
available crystal structure of the catalytic domain of ARTD10 contains the NAD
+
 analogue 3-AB but 
not NAD
+
 itself, models had to be made to assess how NAD
+
 docks into the catalytic center of 
ARTD10. First, it was determined which residues of ARTD10 interact with 3-AB in the crystal 
structure, as summarized in Table 2. In the first column it is listed which atom from which amino acid 
in ARTD10 interacts with which atom in 3-AB. This information is not only useful when planning 
docking studies, but should also be considered when for example mutating amino acids from this list 
as they will most likely results in an inactive enzyme. Phosphorylations occur on tyrosines 919 and 
932 as measured by mass spectrometry (Schmitz, 2010) and are thus highly likely to regulate catalytic 
activity by interfering with the NAD
+
 interaction. 
 
Table 2 Interactions between ARTD10 and 3-AB (V.Losasso) 
 ARTD10 (Residue, atom) 3-AB (atom) 
Hydrogen bonds Ser927, OG O7N 
Gly888, N 07N 
Gly888, O N7N 
Hydrophobic 
interactions 
Leu926, CD2 C5N 
Tyr932, CZ N1N 
Tyr932, CE2 N1N, C2N 
Tyr932, CD2 C2N 
Tyr919, CB C2N, N1N, C6N 
Tyr919, CD1 N1N, C6N 
 
NAD
+
 actually exists in several hundreds of possible conformations, but a recent publication has 
revealed that most NAD
+
-consuming enzymes use NAD in the so-called “scorpion motif” (Lee et al., 
2010). In this publication, 8 different enzymes utilizing NAD
+
 with solved crystal structures are 
analyzed. When superimposing the NAD
+
-conformation in these enzymes, it becomes apparent that 
they are indeed very similar (Figure 32A). All 8 of these were docked into ARTD10, with the best 
result obtained when using the NAD
+
-conformation from the ARTC2.2-NAD
+
 crystal, PDB-accession 
number 1OG3 (Figure 32B). When looking at a mesh figure of ARTD10 with NAD
+
, which displays 
what the model would like when water would run over, it becomes apparent that with this docking the 
NAD
+
 indeed disappears in the catalytic cleft, but the C1-atom of NAD
+
 is facing outward, ready to be 
attached onto a substrate (Figure 32C). 
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Figure 32 Docking of NAD in scorpion formation into the catalytic cleft of ARTD10. (A) Overlay of the conformation of 
NAD+ in different NAD+-consuming enzymes (V. Losasso). (B) Docking of NAD+ into the catalytic site of ARTD10 (V. 
Lossaso). (C) Mesh figure of (B), showing how NAD+ disappears into the catalytic cleft of ARTD10. 
 
Next, models were made of ARTD10-NAD
+
 and GSK3β to further investigate the interaction between 
ARTD10 and GSK3β. For these models to be as accurate as possible, it is essential to gather as much 
experimental information as possible on the modeled proteins, so certain preliminary experiments 
were performed beforehand the modeling procedure was started. It was tested how temperature 
influences the catalytic reaction, by first incubating ARTD10 at 30º for 15 minutes, with and without 
[
32
P]-NAD
+
 and GST-GSKβ (Figure 33A). Temperature itself does not disturb the reaction, as GST-
GSK3β can still be modified after incubation of ARTD10 at 30ºC without [32P]-NAD+. When 
ARTD10 is incubated with [
32
P]-NAD
+ 
for 15 minutes at 30º C, subsequently added GST-GSK3β 
cannot be modified anymore, indicating that the automodification is inhibitory. Furthermore, the 
influence of MgCl2/CaCl2 present in the reaction buffer was tested (Figure 33B), as these may have 
considerable influence on the outcome of docking studies. However, these also do not influence 
ARTD10s activity. Lastly, it was tested whether the presence of GSK3β might also influence the 
modification of other proteins, such as Ran-GTP which was identified as ARTD10 substrate before 
(Schuchlautz, 2008). This was not the case however, both proteins are modified equally well when 
present alone or simultaneously in the ADP-ribosylation reaction (Figure 33C), the used Ran-GppNHp 
is a non-cleavable GTP analog. 
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Figure 33 Assessment of the influence of different factors on ART activity. (A) TAP-ARTD10 was incubated with GST- 
GSK3β for 30 minutes at 30ºC unless indicated otherwise. (B) TAP-ARTD10 was incubated in ADP-ribosylation buffer for 
30 minutes at 30ºC with addition of indicated components to the reaction buffer. (C) TAP-ARTD10 was incubated in an 
ADP-ribosylation assay with GST-GSK3β or Ran-GppNHp alone or together. Results from one preliminary experiment are 
shown. 
 
Since addition of EDTA/EGTA or MgCl2/CaCl2 did not seem to have an influence on catalytic activity 
(Figure 33B), no ions were added as parameter in the docking studies. Several criteria were used to 
limit the search to the bare necessities, to avoid using more computer time than necessary. Because 
GSK3α was also identified as substrate on the ProtoArrays, only sites that are present in both GSK3α 
and GSK3β need to be considered. Initial docking studies were performed with only glutamates or 
aspartates of GSK3β as interacting residues according to the model of substrate-assisted catalysis, later 
on arginines and lysines were also considered because some of the ARTDs were described to modify 
lysines, as summarized in the introduction. Pairs of acidic and basic residues were also considered, to 
test the theory that the acidic residue might indeed serve to stabilize the reaction, in which however 
the neighboring basic residue would be the final acceptor, as described above. A summary of some of 
the candidate-modification sites for the analysis of single amino acids is given in Table 3.  
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Table 3 Summary of the docking study results (V. Losasso). 
Residue Solvent accessibility HADDOCK scoring function Interacting surface (Å
2
) 
GLU53 0.91 -84.3 540.6 
ARG96 65.0 -105.25 567.4 
GLU121 0.91 -80.4 513.4 
ARG180 0.10 -101.3 938.8 
LYS197 0.21 -86.9 1543.1 
LYS205 0.10 -94.9 595.4 
GLU211 0.60 -111.3 521.7 
ASP264 0.56 -105.0 506.8 
GLU279 0.71 -88.0 775.6 
GLU290 1.00 -107.7 556.1 
 
The solvent accessibility indicates how accessible the residue is, where a higher score means a higher 
solvent accessibility and thus higher likelihood of modification. The HADDOCK scoring function 
implements forces like van der Waals and electrostatic forces and should be low for good candidates. 
The interacting surface shows how big the area of the proteins is that is involved in the interaction, 
where a larger interacting area increases the probability of a real hit. It cannot easily be deduced from 
this information which site might be modifies, because these scores cannot be combined into one score 
to create a list of potential modification sites ranging from the best possibilities to the weaker ones. 
 
 
Figure 34 Model of the interaction between GSK3β residue K197 and ARTD10. GSK3β is displayed in light blue, the 
catalytic domain of ARTD10 in grey. Catalytic residues of both enzymes are shown in pink. K197, the putative modification 
site analyzed in this model in shown in red (V. Losasso). 
 
In Figure 34 the interaction between GSK3β’s residue K197 and ARTD10 is shown. GSK3β is 
colored light blue, the catalytic domain of ARTD10 in grey. The residues most important for catalytic 
activity for both enzymes are shown as pink sticks. Labeled in red is K197 of GSK3β. Although this 
residue had a quite high score, mainly because of the large interacting surface, it becomes apparent 
that this particular residue is actually pretty far away from the NAD
+
 moiety in the current model and 
thus unlikely to be modified. 
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Several of the residues listed in Table 3 were mutated and subsequently tested in independent ADP-
ribosylation assays (Figure 35), but the relevant residue has not been identified yet, since all mutants 
tested could still be modified by ARTD10. The method employed here to study these mutants 
unfortunately displays limited sensitivity, as for instance in Figure 35A HA-GSK3β-E53A_E121A 
seems to be no substrate anymore, whereas the triple mutant, HA-GSK3β-E53A_E121A_E279A is 
substrate, indicating that both E53 and E121 are not the relevant site. 
 
 
Figure 35 GSK3 mutants tested in ADP-ribosylation assays. Indicated GSK3β mutants were overexpressed in HeLa cells, 
immunoprecipitated and tested in ADP-ribosylation assays with TAP-ARTD10.  
 
To identify mono-ADP-ribosylation sites in GSK3β, it might be better to analyze the ADP-
ribosylation actually present on GSK3β after an ADP-ribosylation assay than to mutate every putative 
modification site, as this might lead to false positive or false negative results. False positives might be 
caused by conformational changes due to the mutagenesis, thereby making a modification site 
inaccessible. Alternatively, the binding surface might be destroyed instead of the modification site, 
also leading to false positive results. False negatives could occur if the modification site indeed is 
mutated, but where a secondary modification site might arise due to the mutagenesis. To circumvent 
this problem, kinase assays were performed on GSKβ that was immunoprecipitated from U2OS cells 
co-expressing ARTD10 or ARTD10-G888W. It is expected that the mutant in which the modification 
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site is mutated, will not be repressed by ARTD10 since it cannot be modified. Kinase activity should 
then be comparable for the mutant co-transfected with active or inactive ARTD10. 
 
 
Figure 36 Activity of HA-GSK3β mutants co-transfected with dsRed-ARTD10 or dsRed-ARTD10-G888W. U2OS cells 
were transfected with indicated GSK3β plasmids and either active or inactive ARTD10. 24 hours after transfection, cells 
were lysed and GSK3β immunoprecipitated. Immunoprecipitated material was used in kinase assays to determine activity, 
with an exemplary IP control blot shown. Data are represented as mean ±SD of triplicate measurements of a representative 
experiment. 
 
HA-GSK3β wildtype was used as control and indeed, co-expression of dsRed-ARTD10-G888W leads 
to a higher kinase activity than co-expression of dsRed-ARTD10. The basal expression levels of the 
different mutants slightly differ, however co-expression of ARTD10 does not influence expression of 
these mutants, making it possible to compare co-expression of ARTD10 wildtype with ARTD10-
G888W, but not between mutants (Figure 36). GSK3β-D77A_D200A lacks activity, which might be 
expected since D200 is part of the DFG-motif, which is crucial for kinase activity (Kornev et al., 
2006). Should one of these aspartic acid residues be the relevant amino acid for mono-ADP-
ribosylation, then this will be missed in this type of assay. Both triple mutants tested here, HA-
GSK3β-R141A_R144A_R148 and HA-GSK3β-E211A_D264A_E290A are active. Both have 
increased kinase activity when co-transfected with dsRed-ARTD10-G888W, comparable to the 
induction of wildtype GSK3β, indicating that these 6 sites are not the mono-ADP-ribosylation sites 
and are not crucial for kinase activity. The triple mutant HA-GSK3β_E53A_E121A_E279A behaves 
similar (data not shown), indicating that these three amino acids are also not the modification sites. 
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In future research, these bioinformatical models could be further refined and ideally describe the 
interaction of relevant residues within GSK3β with the NAD+ in the catalytic cleft, as this might be 
more important for catalysis than closeness to the residues of the catalytic triad. Alternatively, the 
distance between the relevant residue and the C1-atom of NAD
+
 that becomes attached to the 
substrates could be calculated, to implement the distance between those in the evaluation. This might 
lead to better fitting models that give better chances of identifying the relevant sites. Additionally, 
PTMs often occur on flexible protein regions (Gao and Xu, 2012). The flexible N-terminal extension 
is missing in the rigid crystal structure used for these docking studies and for example the DFG-motif 
is in a fixed state that is not reflective of its state in a watery environment, where multiple 
conformations are possible. It is possible that certain amino acids are weak candidates according to 
these models, but in truth are more flexible than the structure reveals and thus suited as modification 
site despite low score. Putative modification sites present in flexible regions might therefore be missed 
in these studies. Since these models could not provide a definite answer yet to the question which sites 
in GSK3β ARTD10 is modifying, we developed alternative methods based on mass spectrometry and 
peptide arrays to further analyze the different possibilities. 
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Mapping modification sites using mass spectrometry and peptide arrays 
As mentioned in the introduction, mapping of ADP-ribosylation sites using conventional mass 
spectrometry methods is not trivial. Since the major problem is the instability of the linkage between 
ribose and substrate, regardless of the amino acid modified, methods were developed to circumvent 
this particular problem. Two similar approaches were employed simultaneously and optimized using 
the automodified catalytic domain of ARTD10. After ADP-ribosylation assays with or without β-
NAD
+
 as control, in-solution trypsin digests were performed. Subsequently the samples were desalted 
and loaded onto different columns. To assess whether the conditions for trypsin digestion and 
subsequent desalting were optimal, tests were performed with digested and subsequently desalted 
material. As expected, no clear peaks corresponding to mono-ADP-ribosylated peptides could be 
detected (data not shown). Next, peptides mono-ADP-ribosylated with biotin-ADP-ribose were 
incubated with streptavidin-dynabeads, samples mono-ADP-ribosylated with regular β-NAD+ were 
incubated with ProSep BP essentially as described in (Rosenthal et al., 2011). After subsequent 
washing steps, bound peptides were eluted and when necessary desalted again, before drying and 
subsequent analysis by mass spec. Different washing conditions were tested especially for the 
streptavidin-dynabeads since high background binding was present without stringent washing of the 
beads (data not shown). Due to the highly stable interaction between streptavidin and biotin, harsh 
washing conditions, such as RIPA lysis buffer, could be chosen for further experiments to reduce 
background signals without disturbing the specific interaction. The advantage of this method is that 
only the mono-ADP-ribosylated peptides should be present in the final mass spectrometric spectrum, 
so it should not matter if the ADP-ribose is cleaved during the ionization procedure. Input samples 
were measured from all samples analyzed, containing 10% of the total amount of material. To 
generate enough material for mass spec analysis, 5 ADP-ribosylation assays were performed in 
parallel for each sample and added to one column of beads after digestion. Unfortunately, 
contradicting the earlier report introducing this method for ADP-ribosylation performed by ARTD1, 
we were not able to consistently measure a peptide specifically binding to the columns that could 
correspond to a modified peptide.  
 
The next step could be the treatment of trypsin digested mono-ADP-ribosylated samples with MDO2 
to remove the ADP-ribose completely before mass spec analysis. That should take care of the ADP-
ribose and render identifiable peaks in the spectra. Alternatively, digested mono-ADP-ribosylated 
samples treated with PDE should render peptides with an identifiable modification, the phospho-
ribose. By comparing non-modified peptides with PDE-treated peptides and mono-ADP-ribosylated 
peptides, it should be possible to define which peptides are modified by ARTD10 and how mono-
ADP-ribose is cleaved off exactly during MALDI analysis. Of course, the other possibility would be 
to try to tackle this problem with other mass spec methods such as ETD. 
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One-dimensional chromatography ADP-ribosylation maps 
An alternative method that might allow for better recovery of mono-ADP-ribosylated peptides and to 
reduce background is chromatography. This method has been used to map phosphorylation of peptides 
(Luscher and Eisenman, 1992; van der Geer and Hunter, 1994), before mass spectrometry became a 
common method. First, ARTD10 was mono-ADP-ribosylated with radioactively labeled NAD
+
 and 
loaded on SDS-PAG. To assess the incorporated radioactivity, the gel was exposed to X-ray film at 
RT (Figure 37A).  
 
 
Figure 37 1D chromatography of mono-ADP-ribosylated GST-ARTD10(818-1025). (A) GST-ARTD10(818-1025) or 
GST-ARTD10(818-1025)-G888W were used in ADP-ribosylation assays with [32P]-NAD and analyzed by coomassie. The 
wet gel was exposed to film at RT for 90 minutes. (B) The coomassie bands from (A) were extracted from the gel and 
digested with trypsin. Digested peptides were loaded on cellulose plates and separated by chromatography in 1 direction. 
Two different chromatography buffers were tested. 
 
The corresponding coomassie band was cut out to enable in-gel digestion of the relevant proteins. 
Digested peptides were then spotted on cellulose chromatography plates in pH 1.9 buffer as described 
before (van der Geer and Hunter, 1994). After a chromatography run of approximately 12 hours, 
plates were exposed to X-ray film at -80ºC (Figure 37B). It becomes apparent that there is only one 
major automodification peptide within GST-ARTD10(818-1025) and that there are either less-well 
modified second sites or that the trypsin digest was incomplete. Two different chromatography buffers 
were employed, phospho chromatography buffer and isobutyric acid buffer to be able to separate also 
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peptides running very similar in one buffer (van der Geer and Hunter, 1994). The two buffers gave 
similar patterns, with one major automodification site present and some minor modification sites. This 
method can now be repeated for other substrates in order to analyze how many modification sites are 
present. Moreover, material can be eluted from these plates and measured with mass spec, to identify 
the peptides that modified. Alternatively, partial trypsin digests could be performed on protein 
modified with [
32
P]-NAD
+
. After SDS-PAGE separation, the radioactive bands correspond to the area 
wherein the modification takes place. Those can subsequently be identified by regular MALDI 
analysis. Narrowing down the area of interest will make mass spec analysis of mono-ADP-ribosylated 
samples using the methods described above less complex. 
 
Peptide arrays to define consensus motifs 
Since it is not known yet what preferences ARTD10 has in its substrates or whether there might be 
some consensus motif, we decided to screen peptide libraries for good substrate peptides. For this 
purpose peptide arrays from JPT (Berlin) were employed, wherein peptides are spotted directly on a 
glass surface. The method used to probe these arrays is similar to the method described above for the 
ProtoArrays, allowing a fluorescent readout due to the binding of streptavidin-AlexaFluor647 to 
biotin-ADP-ribose containing peptides. Since ARTD10 mono-ADP-ribosylates core histones, it is 
expected that certain peptides derived from core histones should be modified. Two different sets of 
arrays were probed. The first set contained histone tail peptides, in which all of the different currently 
known PTMs were present but only histone peptides with known posttranslational modifications were 
spotted, indicating that not the entire histones are present on these arrays. The PTMs on these histones 
are quite interesting, as it was reported before that acetylated histones carry more ADP-ribose than 
their non-acetylated versions (Golderer and Grobner, 1991). Indeed, ARTD10 modifies the first 
stretch of amino acids of H4 best when acetylated at lysine 5, 8 and/or 16, although the overall 
incorporated signal is relatively weak. Modification of K20 by methylation or acetylation seems to 
inhibit modification (Figure 38). Curiously, the first peptide of H4, with the sequence 
SGRGKGGKGLGKGGAKRHRK, does not contain any glutamic or aspartic acid. It is possible that 
because no specific modification site is available in those peptides, ARTD10 becomes unspecific and 
modifies other residues with very low kinetics, hence the low signals. This is a known problem for 
example for GSK3β, that is also known to be promiscuous in in vitro assays, but which has a lot 
higher specificity in cells due to spatial and temporal restrictions (Sutherland, 2011).  
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Figure 38 Overview of the mono-ADP-ribosylation of an H4-peptide carrying different other PTMs. Histone-tail arrays 
were incubated with TAP-ARTD10 and bio-NAD+. A heat-map was generated to vizualize the relative modification of each 
peptide. Red reflects well-modified peptides, the weaker modified peptides are indiciated in yellow.  
 
The second set of arrays used thus contained peptides covering the entire histone tails, divided in 
overlapping peptides of 20 amino acids. Additionally, peptides are spotted with all known 
modifications that occur on histone tails, such as methylation and acetylation. It is expected that better 
hits can be identified on these arrays, since now the histones are covered completely. It should be 
possible to verify at least glutamate 2 of H2B (Moyle and Muir, 2010) as modification site for 
instance, moreover it would be interesting to identify the relevant amino acids on the other histones as 
well. Finally, it should be possible to narrow down the site of modification to a few amino acids, since 
multiple overlapping peptides should be identified for each modification site. 
 
When incubating these arrays with 1 μg TAP-ARTD10 and 25 μM bio-NAD+, no peptide seems to be 
modified above background level (Figure 39A). We thus decided to use double amounts of these 
reagents to increase signal strength (Figure 39B). Apparently, bio-NAD
+
 can bind to these peptides 
non-enzymatically, perhaps through glycation, since under these conditions signals are also present in 
the BSA only control slide. Moreover, these amounts of TAP-ARTD10 seem to stick to the array 
surface quite efficiently, thereby causing substantial overall background signals. 
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Figure 39 Scans of PepStar Histone Tail Arrays. Peptide arrays were incubated with (A) 1 μg TAP-ARTD10 or BSA as 
indicated and 25 μM bio-NAD+ or (B) 2 μg TAP-ARTD10 or BSA as indicated and 50 μM bio-NAD+. 
 
By manually comparing each spot, positive hits could be identified nevertheless. Interestingly, of the 
peptides derived from H4, the peptide with the highest relative signal when comparing intensities of 
ARTD10 and control incubation, is again the first peptide containing the first 20 amino acids, even 
though as mentioned this peptide lacks acidic amino acids. For H3, peptides overlapping with the 
IRRYQKSTELLIRKLPFQRL-peptide that contained the STE-motif were best modified by ARTD10. 
This would be potentially more interesting and should be followed-up on, by trying to modify these 
peptides in in vitro assays in solution to verify this result. 
 
Additionally two peptides derived from GSK3β, 71-YQAKLCDSGELV and 194-
AVLKLCDFGSAK, containing the K/RxxD/ExG motif, were used to test if these amino acids are the 
modification site in GSK3β. These sites could not be tested as modification site in kinase assays with 
GSK3β mutants, since these mutants per se are devoid of kinase activity (Figure 36). Unfortunately, 
these peptides could not be modified in in vitro ADP-ribosylation assays (data not shown). They also 
had no inhibitory effect on ADP-ribosylation assays on GST-GSK3β, indicating that these peptides do 
not compete for modification and thus are not being modified (data not shown). This might imply that 
ARTD10 cannot modify peptides, either because it needs a certain structure for catalysis, or maybe it 
needs an increased binding surface. For the GSK3β peptides analyzed, it is also likely that they do not 
contain the modification site and are thus negative in ADP-ribosylation assays. The peptides present 
on the peptide arrays should contain modification sites however, as ARTD10 was reported before to 
modify glutamate 2 of H2B (Moyle and Muir, 2010), supporting the notion that ARTD10 needs more 
than just a small stretch of amino acids to be capable of catalysis. This means that peptide arrays are 
not suited to study the ADP-ribosylation reaction by ARTD10 and that alternative methods have to be 
employed to possibly define a consensus motif for ARTD10 substrates. This challenge has not been 
undertaken for any of the ARTD or ARTC enzymes so far. 
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“As our circle of knowledge expands, 
so does the circumference of darkness surrounding it.” 
A. Einstein 
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ProtoArrays are a highly useful tool to identify ARTD substrates 
The results of the screen for ARTD10 substrates presented here have been thoroughly validated. All 
full-length proteins that were tested, no matter how they were purified, could be confirmed as 
ARTD10 substrate, indicating that the identified hits are real substrates at least in in vitro assays. 
These kind of arrays can now be used to screen for substrates of the other ARTD or also ARTC 
enzymes and thus represent a novel method to approach this PTM. A valid question to be addressed 
next is whether all those proteins are also ARTD10 substrates in cells, to investigate whether the same 
is true as for GSK3β, that some of the in vitro substrates are actually in vitro artifacts (Sutherland, 
2011). The same is true for the identified ARTD8 substrates; those will have to be validated in vitro as 
well as in cells. The fact that many unique substrates were identified, indicates that these enzymes 
have unique roles in cellular processes and do not function completely redundant, in spite of a highly 
similar catalytic domain. 
 
The percentages of kinases and secreted molecules are remarkably high. Future research will have to 
reveal whether mono-ADP-ribosylation takes place on a common motif of the kinases, such as the 
aforementioned DFG motif (Kornev et al., 2006) or on another conserved domain, thereby causing so 
many kinases to be substrate. Which in itself would be very interesting, as mono-ADP-ribosylation 
could then represent a general regulatory mechanism of kinases. Regarding the secreted factors, the 
obvious next step to take is the modification of a recombinant growth factor and test whether receptor 
binding capacities are impaired, such as reported before for PDFG-B (Saxty et al., 2001). 
Additionally, the question whether or not there is ARTD10 present in the extracellular matrix under 
certain circumstances or whether it may be involved in secretion pathways is very intriguing as well. 
HMGB1 was reported to be secreted highly poly-ADP-ribosylated from cells, so apparently a link 
already exists between ADP-ribosylation and secreted proteins, although this is not clear yet 
mechanistically (Davis et al., 2012). 
 
Mono-ADP-ribosylation reversibly inhibits GSK3β activity 
This thesis is the first work that describes not only the mono-ADP-ribosylation of a kinase by an 
eukaryotic intracellular enzyme, but also that mono-ADP-ribosylation inhibits enzymatic activity. 
Such direct functional consequences have not been reported yet for any protein mono-ADP-
ribosylated by ARTDs, but may actually be only the tip of the iceberg, if the other substrates identified 
are influenced likewise. A third novelty in this report is the description of MDO2 as de-ADP-
ribosylating enzyme for GSK3β and for ARTD10 itself. Until now, it was not clear which enzyme is 
responsible for the removal of the last ADP-ribose moiety. Because mono-ADP-ribosylation functions 
as a non-competitive inhibitor in contrast to the well-studied serine 9 phosphorylation (Dajani et al., 
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2001; Frame et al., 2001), it is probable that different signals regulate GSK3β in different manners, 
thereby perhaps modulating certain GSK3β substrates without affecting others. These findings raise 
multiple additional questions. Does MDO2 also have some protein backbone specificity, or can it 
remove any ADP-ribose moiety? When are MDO2 and ARTD10 expressed, how is their activity 
regulated? Is overall mono-ADP-ribosylation in physiological conditions kept low in cells by MDOs, 
or are basal levels high? Is there a constant addition and removal of the mono-ADP-ribose, or are 
MDO2 and ARTD10 usually inactive in cells? All these questions have to be addressed in future 
studies to clear how mono-ADP-ribosylation is regulated in cells, under normal and pathological 
conditions. Currently, it is difficult to study regulation of ARTD10, since there are not many possible 
read-outs yet. Intracellular localization can be studied and in vitro activity can be tested, but further 
read-outs, such as assays to test ADP-ribosyltransferase activity in cells have to be developed still. 
 
Reliable tools to study ADP-ribosylation sites are still lacking 
The docking studies presented here are in principle useful to study the interaction between enzyme and 
substrate. The generated model between ARTD10 and NAD
+
 can be employed to study which 
residues in the catalytic cleft are important in the interaction of ARTD10 with NAD
+
. It is however 
difficult to obtain data with a high predictive power using this method, because the crystal structures 
used are confined in one conformation. The modification site might be in a flexible region that is 
captured in a non-favorable state in the crystal and thus be false negative in the docking studies. The 
attempts at site mapping that are described here, show that it is also not straightforward to directly 
measure mono-ADP-ribosylation, in agreement with earlier publications on this topic (Hengel and 
Goodlett, 2012). Mass spec methods regularly used for phosphorylation fail when applied to mono-
ADP-ribosylation and even published methods that were developed to measure ADP-ribosylation 
could not be applied successfully. Furthermore, the obtained hints that ARTD10 cannot modify 
peptides further complicates matters, as peptide arrays commonly used to study other enzymes are of 
no use. Thus other methods have to be developed to define a putative consensus motif. Additionally, 
the generation of an antibody is difficult without a good substrate peptide that can be modified 
efficiently. To solve these difficulties, methods have to be developed to create mono-ADP-ribosylated 
antigen on large scale, which would ideally be modified chemically to strengthen the labile bonds such 
as the PDE-resistant NAD[S] (Meyer et al., 1984). Alternatively, one could develop antibodies using 
phage display, by first positively selecting binding-modules against mono-ADP-ribosylated proteins 
and subsequent negative selection against the unmodified protein. 
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Concluding remarks 
This work shows that mono-ADP-ribosylation has the potential to become as important as better 
studied PTMs such as phosphorylation, especially considering the diversity of identified substrates, 
the impact on GSK3β activity and the fact that it could be shown that this PTM is reversible. 
However, mono-ADP-ribosylation is probably not as widespread as some other PTMs, because there 
are not as many responsible enzymes. The current state of the field can probably be best compared 
with the phosphorylation field around 30 years ago, where people first came to realize that this 
modification could very well be important, but where sophisticated tools to study it were still lacking. 
This means that right now, the “old” tools used in the beginning of the phosphorylation era might be 
most useful to study ADP-ribosylation, such as partial trypsin digests and chromatography. However, 
in the long run someone has to invest in the creation of better-suited reagents to be able to fully 
comprehend the physiological relevance of the posttranslational modification mono-ADP-ribosylation. 
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“Lord Polonius: What do you read, my lord? 
Hamlet: Words, words, words. 
Lord Polonius: What is the matter, my lord? 
Hamlet: Between who? 
Lord Polonius: I mean, the matter that you read, my lord.” 
 
William Shakespeare 
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I 
Abbreviations 
ADP:  adenosine diphosphate 
ADPr:  adenosine diphosphate ribose 
ATP:  adenosine triphosphate 
ARH:  ADP-ribosylhydrolase 
ART:  ADP-ribosyltransferase 
ARTC:  ADP-ribosyltransferase cholera toxin like 
ARTD:  ADP-ribosyltransferase diphtheria toxin like 
BAL1-3: B-aggressive lymphoma 1-3 
BBAP:  B-cell aggressive lymphoma and BAL1 binding partner  
BSA:  bovine serum albumin 
CB:  coomassie blue 
CDP:  Cdc4-phosphodegron 
CID:  collision-induced dissociation 
CoaSt6: co-activator of STAT6 
DAPK1/3 death associated protein kinase 1/3 
DDX17: p72 DEAD box RNA helicase 
eEF2:  eukaryotic elongation factor 2 
ELM:  eukaryotic linear motif 
ETD:  electron-transfer dissociation 
GSK3β: glycogen synthase kinase 3β 
GST:  glutathione S-transferase 
IFN:  interferon 
IKKε:  inhibitor of nuclear factor kappa-B kinase subunit epsilon  
IP:  immunoprecipitation 
IRS1:  insulin receptor substrate 1 
ISG:  interferon-stimulated gene 
MALDI: matrix-assisted laser desorption/ionization 
Mass spec: mass spectrometry 
MCCA: methylcrotonyl-Coenzyme A carboxylase 1 alpha 
MDO2:  O-acetyl-ADP-ribose deacetylase MacroD2 
MMLV: Moloney murine leukaemia virus 
NAD:  nicotinamid adenine dinucleotide 
NAM:  nicotinamid 
NEK6:  never in mitosis A-related kinase 
NES:  nuclear export signal 
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II 
NF-κB  nuclear factor NF-kappa B 
NICD:  NAD
+
-induced cell death 
NLS:  nuclear localization signal 
PAR:  poly-ADP-ribose 
PARP:  poly-ADP-ribose polymerase 
PARG:  poly-ADP-ribose glycohydrolase 
PDB:  Protein Data Bank 
PDE:  phosphodiesterase 
PCCA:  propionyl coenzyme A carboxylase alpha polypeptide 
PRKCZ: protein kinase c zeta 
P-TEFb: positive transcription elongation factor b 
RRM:  RNA recognition motif 
RT:  room temperature 
SCF:  SKP1-Cul1-RBX1 
SINV:  Sindbis virus 
SRPK2: serine/arginine rich protein kinase 2 
STAT:  signal transducer and activators of transcription 
TAP:  tandem affinity purification 
TFA:  trifluoroacetic acid 
TOF:  time-of-flight 
UBA:  ubiquitin activating enzyme 
UBC:  ubiquitin conjugating enzyme 
UIM:  ubiquitin interaction motif 
VEEV:  Venezuelan equine encephalitis virus 
WB:  Western blot 
WCL:  whole cell lysate 
ZAP:  zinc-finger antiviral protein 
ZAPS:  zinc-finger antiviral protein short isoform 
 
 
Attachments | Layman’s summary 
 
III 
Layman’s summary 
Enzymes are molecules that catalyze a reaction without being used in that reaction themselves. In 
washing powder, there are for example enzymes that break down fat, the so-called lipases. They will 
do this over and over again, until all fat is gone. There are not only enzymes that destroy other 
molecules; there are also enzymes that can help build things. An example of this are the enzymes that 
work together to copy DNA, the material carrying the traits you inherited from your parents. 
 
The cells that together form the human body contain thousands of enzymes per cell. For some of them, 
it is clear what they do, whereas for others it isn’t. For some of the ones with known function, it is also 
known that they play a role in certain diseases and thus therapies have been developed to influence the 
function of those enzymes in cells. In certain types of breast cancer for example, there can be 
malfunctioning of DNA repair systems, allowing the cells to mutate. ARTD1, formerly called PARP1, 
is an enzyme that, amongst other functions, recognizes where the DNA is broken and attaches a flag 
onto those spots. Other enzymes will then come to those flags and repair the broken DNA. If one now 
blocks ARTD1 in certain types of cancer, the broken DNA will not be repaired anymore. The cancer 
cells will get so many breaks in their DNA that eventually they die. Healthy cells will not die as 
quickly as those cancer cells because of an additional DNA repair system that is still working in those 
healthy cells. 
 
The aim of this work was to study an enzyme, ARTD10. Already known is that ARTD10 can also 
attach flags to other molecules, but different flags from the ones made by ARTD1. In this thesis it is 
described how we searched for molecules that receive flags from ARTD10. Subsequently I 
investigated how this flag influences the function of an 
 it is 
shown that this reaction is reversible, as there is another enzyme, MDO2, which catalyzes the reverse 
reaction and removes the flag again. Lastly, tools were investigated that can be used to study these 
little flags, since there is nothing except radioactive labeling that currently allows us to see the flags. 
Once it is clear what the function of ARTD10 is, it might become a target for specialized therapies as 
well, but therefore we need to gain further understanding first. 
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Scientific contributions 
Publications in scientific journals: 
Feijs KLH, Kleine H, Braczynski A, Forst AH, Herzog N, Verheugd P, Linzen U, Kremmer E, 
Lüscher B. Identification of ARTD10 substrates and regulation of GSK3β by mono-ADP-
ribosylation. Manuscript submitted 
 
Rosenthal F*, Feijs KLH*, Bonalli M, Frugier E, Forst AH, Imhof R, Winkler HC, Caflisch A, 
Hassa PO, Lüscher B, Hottiger MO. Macrodomain-containing proteins are novel mono-ADP-
ribosylhydrolases. Nature Structural and Molecular Biology, manuscript in revision 
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Communications, manuscript in revision 
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Presentations at scientific meetings 
Feijs KLH, Kleine H, Braczynski A and Lüscher B. Identification of ARTD10 substrates using 
protein microarrays and characterization of mono-ADP-ribosylation as inhibitory mechanism of 
GSK3β. Poster presented at the 4th EMBO Meeting, 22-25 September, Nice, France (2012). 
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